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MicroRNAs are short RNA molecules that are central to the regulation of many cellular and
developmental pathways. They are processed in several stages from structured precursors in
the nucleus, into mature microRNAs in the cytoplasm where they direct protein complexes to
regulate gene expression through, often imperfect base-pairing with target messenger RNAs.
The broad aim of this project is to better understand how polymorphisms and new mutations
can disrupt microRNA processing and targeting, and ultimately define their contributions to
human disease.
I have taken two approaches towards this. The first approach is to comprehensively identify
the microRNA targets by developing and applying a novel computational pipeline to identify
microRNA binding events genome-wide in RNA-RNA interaction datasets. I use this to
examine the transcriptomic diversity of microRNA binding, finding microRNA binding events
along the full length of protein coding transcripts and with a variety of non-coding RNAs. This
reveals enrichment for non-canonical microRNA binding at promoters and intronic regions
around splice sites, and identifies highly spatially clustered binding sites within transcripts
that may be acting as competitive endogenous RNAs to compete for microRNAs, effectively
sequestering them. Using statistical models and new cell fractionated RNA-seq data, I rank the
features of microRNAs and their binding sites which contribute to the strength and specificity
of their interaction to provide a better understanding of the major determinants of microRNA
targeting.
The second approach is to directly identify DNA sequence changes in microRNA precursors
that alter processing efficiency affecting mature microRNA abundance which are routinely
overlooked in the search for disease or trait associated causal variants. I have systematically
screened public datasets for both rare and common polymorphisms that overlap microRNA
precursors and are correlated with mature microRNA levels as measured in short RNA
sequencing. I use these eQTL SNPs to examine the most important microRNA precursor
regions and sequence motifs. Several of these SNPs have been observed as risk factors in
cancer or other clinically relevant traits, and correlated with microRNA processing efficiency.
I demonstrate that a specific DNA change which is known to be important in the development of
some cancers, is located in a microRNA precursor and affects the balance of its two products,
miR-146a-3p and miR-146a-5p, that can be produced from that single precursor providing
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new insights into the mechanisms of microRNA production and the aspects of genetic mis-
regulation that result in cancer. I find further examples of common human polymorphisms
that appear to affect microRNA production from their precursors, several of these variants
are independently implicated in human immune disease, cancer susceptibility and associated
with other complex traits. As they exhibit a molecular phenotype and immediately lead to
mechanistic hypotheses of trait causality that can be tested, these variants could provide a route
into the frequently intractable problem of mechanistically linking non-coding genetic variation
to human phenotypes. Applying similar studies to patient DNA has revealed rare and unique
DNA changes that are now candidates for causing human disease that are being subject to
follow-up experimental studies. Collectively this work has started to define which sequences
changes in microRNAs are likely to disrupt their function and provides a paradigm for the
analysis of microRNA sequence variants in human genetic disease.
Lay summary
Most cells of the human body have essentially the same genetic blueprint in their DNA.
What makes a skin cell different from a neuron and both different from a muscle cell are the
distinct ranges and amounts of products that are made from that blueprint. Careful regulation
of the dosage of those products, often proteins, is central to health and development, and
disrupted regulation can result in disease and is the molecular basis of cancer. Small RNA
molecules termed microRNAs are known to be a key component of the dosage regulation
system. microRNAs are produced from longer intricately folded precursor RNAs and work
by targeting proteins to longer RNA molecules containing sequences related to the microRNA,
often causing those targets to be broken down.
The broad aim of this project is to better understand how DNA sequence changes can disrupt
microRNAs and ultimately contribute to human disease. I have taken two approaches to this,
the first to comprehensively define what the microRNA targets are and how those targets are
found by the microRNA, the second approach is to directly identify DNA sequence changes
that alter the amount of microRNA produced. Together these approaches can implicate how
changes in a microRNA or its production can have knock-on effects.
I have developed new computational tools to analyse high-throughput data showing microRNA
interactions. For the first time this allows the whole genome scale search for targets without
making assumptions about the type of target. This has revealed several new types of microRNA
target but also confirmed the importance of the previously known type of target. This approach,
coupled with some new experimental data also allowed me to measure the specificity of
interactions and where within a cell they are taking place.
Looking at how changes in the DNA blueprint for microRNAs affects their production from
precursors, I have found some DNA changes causing either more or less microRNA to be
produced. I demonstrate that a specific DNA change which is known to be important in the
development of some cancers, is located in a microRNA precursor and affects the balance of
two products that can be produced from that precursor. This provides new insights into the
mechanisms of microRNA production and the genetic mis-regulation that results in cancer.
I also find further DNA changes that appear to affect microRNA production from their
precursors, several of these changes are common in the human population and also seem to
correspond to clinical traits such as blood lipid levels. Applying similar studies to patient DNA
iv
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has revealed rare and unique DNA changes that are now candidates for causing human disease.
Collectively this work has started to define which sequence changes in microRNAs are likely to
disrupt their function and provides a paradigm for the analysis of microRNA sequence variants
in human genetic disease.
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Small RNAs are typically ∼20-30nt in length identified in animals, plants and fungi with
a variety of known roles in gene regulation. They can be categorised into several broad
classes of small RNA species including microRNAs, PIWI-associated RNAs (piRNAs) and
small interfering RNAs (siRNAs) with others continually being added with varying production
and effector pathways. Small RNAs act through interactions — inter- or intra-molecular
base pairing RNA–RNA interactions where A pairs with U and G with C, and RNA–protein
interactions — in the formation of functional complexes, best known as regulators of gene
expression via base-pairing to messenger RNA (mRNA) affecting the production of their
protein products.
1.1 Discovery of small RNAs
1.1.1 microRNAs
Small RNA directed gene regulation was discovered in the nematode worm C. elegans where
the gene lin-4 was identified through a developmental screen as a negative trans regulator of
lin-14. Lin-4 controls the transition from the first to the second larval stage. It was located
through positional cloning and found to be unlikely to encode a protein. Two transcripts
were found corresponding to the lin-4 locus, one 61nt in length and the other 22nt — which
would now be called the pre-microRNA and microRNA respectively — this smaller RNA
being complementary to the 3'UTR of the lin-14 gene [1, 2]. Lee et al observed that “lin-
4 may represent a class of developmental regulatory genes that encode small antisense RNA
products”.
A second regulatory small RNA was discovered again through a developmental screen in C.
elegans, this time for genes which suppressed the synthetic sterile phenotype of a strain with
lin-14 and egl-35 mutants [3]. Mutants of let-7 were strongest to retard the heterochronic
defects of the lin-14 background, and mutants of let-7 displayed lethal phenotypes with larval
1
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cell fates being reproduced during the adult stage of development. Similarly to lin-4, let-7 was
found to correspond to no conventional (protein-coding) gene product, however evolutionary
conservation analysis between Caenorhabditis species identified a conserved 26-bp region
overlapping one let-7 point mutation. Northern blot analysis detected a 21nt RNA transcript
from this conserved region. Expression of this transcript was found to be temporally regulated
– expressed only in the L4 and adult stages – in agreement with its observed functions.
Regions complementary to let-7 were found in the experimentally determined sequences of
heterochronic genes, present only in the 3'UTRs of lin-14, lin-28, lin-41, lin-42 and daf-12.
∼21nt small RNAs such as lin-4 and let-7 came to be known as microRNAs.
As more genome sequences were becoming available evolutionary analysis identified similar
small RNAs in a variety of other species. Initial studies found homologs of lin-4 only in the
genus Caenhorabditis, however homologs of let-7 were found in a wide range of animal species
[4].
The discovery of additional microRNAs has proceeded through three main approaches:
capture, isolation and sequencing; forward genetics; and computational prediction. Other than
the initially discovered lin-4 and let-7 few microRNAs have been identified in loss of function
genetic screens. Through comparative genomics and cDNA cloning other microRNAs were
identified in C. elegans some of which were temporally regulated during development with
potential orthologs in Drosophila and humans [5, 6, 7]. Direct cloning or sequencing of small
RNAs[8, 9, 10] and computational prediction have been the most commonly used methods
to detect microRNAs. Computational methods relying on the prediction of hairpin structures
where RNA molecules fold and base-pair with another section of the same strand forming a
U shape, and evolutionary conservation of microRNA sequences[11] where some microRNAs
being highly conserved while others are evolving rapidly[12].
Other small RNA types have also been classified including siRNAs and piRNAs and snoRNAs
which share some sequence, structural or functional properties of microRNAs but are
sufficiently different to warrant a distinct classification.
1.1.2 siRNAs
The introduction of small double stranded RNA (dsRNA) molecules into cells was found
to interfere with endogenous RNAs more potently than either sense or antisense RNA
individually. These dsRNAs are processed to become small interfering RNAs (siRNAs),
small RNA molecules similar to microRNAs, and associate with the same protein complex to
silence specific targets via complementary base pairing, functioning in human cell culture[13].
This effect was termed RNA interference (RNAi)[14], and its discoverers Andrew Fire and
Craig Mello were awarded the 2006 Nobel Prize in physiology or medicine. Since then
small hairpin RNA (shRNA) libraries of dsRNAs have been developed as a tool for loss-of-
function screens[15] and are now widely used. Also RNAi based therapeutics have been under
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investigation with some advantages over traditional small molecule drugs such as specificity,
however delivery strategies that can be used in clinical settings remain a major challenge [16].
1.1.3 piRNAs
PIWI-interacting RNAs (piRNAs) are 21–30nt single stranded RNAs named for their
association with PIWI proteins. PIWI proteins were identified as necessary for germline
integrity: piwi was found to be necessary for self-renewal of germ cells in Drosophila[17].
Aubergine, another PIWI clade member is necessary for pole cell formation to produce
functional oocytes [18]. Similar roles were found in mammals with miwi (murine piwi) being
essential for spermatogenesis [19] and Mili (Miwi like Piwil2 (piwi like 2)) also being essential
for spermatogenesis in mice [20]. Mutations in members of the PIWI gene family were also
seen to affect mobile genetic elements, with piwi silencing the endogenous retrovirus gypsy,
and aubergine repressing the telomere retroelement TART. Identification of the guide RNAs
associated with these PIWI clade proteins initially identified RNAs 29-30nt in length in mice
and rats which were mostly clustered into genomic regions less than 100kb in length with
expression in the testes essential to spermatogenesis [21, 22, 23, 24].
1.1.4 snoRNAs
Small nucleolar RNAs (snoRNAs) are a class of non protein-coding small RNAs longer than
the previous examples at ∼70-200nt, best known for guiding the modification of other non
protein-coding RNAs including ribosomal, small nuclear and transfer RNAs (rRNA, snRNA
and tRNA respectively). U3 - the most abundant snoRNA has long been known to bind to
pre-ribosomal RNA[25], with snoRNAs functioning through the direct base-pairing of part of
their sequence[26].
1.2 Argonaute proteins
Three types of small RNAs discussed here (microRNA, siRNA and piRNA) act primarily
through binding to members of the argonaute family of proteins. These were first observed
in the C. elegans RNA interference deficient (rde) mutants [27], which were discovered in a
screen for RNAi mutants by mutagenising wild-type animals and culturing them on a bacterial
lawn expressing dsRNA complementary to the essential gene pos-1. The F2 generation could
then be searched for individuals able to produce viable progeny. These mutant strains were
subsequently examined for their RNAi activity in somatic cells by injecting dsRNA targeting
the collagen gene sqt-3 and the body muscle structural gene unc-22 and examining animal
shape and the presence of the body twitching phenotype. The rde-1, rde-3, rde-4 and mut-2
activities appeared to be required for RNAi of all genes analysed whereas rde-2 and mut-7
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activities were specific to RNAi in the germline but not somatically expressed genes [27]. This
observation led to the functional distinction between production of siRNA from longer dsRNA,
and the subsequent utilisation of the produced siRNAs [28]. rde-1 and rde-4 were seen to form
a complex with dicer (dcr-1) an RNAseIII nuclease responsible for cleaving dsRNAs in the
production of small RNAs for RNAi [29, 30].
The argonaute family of proteins in animals can be divided into two main subfamilies, the AGO
subfamily or clade are named for their similarity to the Arabidopsis thaliana AGO1 protein,
and the PIWI clade which are homologous to the Drosophila melanogaster Piwi protein [31].
AGO proteins bind microRNAs and siRNAs, leading to post-transcriptional gene silencing
(PTGS or RNAi). Whereas PIWI proteins bind piRNAs and are expressed mainly in germ cells
where they repress transposable elements.
Humans have eight argonaute family members, Piwi-like 1-4 (PIWIL1, PIWIL2, PIWIL3,
PIWIL4) of the Piwi clade and human AGO 1-4 (AGO1, AGO2, AGO3, AGO4) of the AGO
clade [31]. The AGO members are closely related and appear to be ubiquitously expressed.
While in some species different AGO associated small RNA species appear to bind to distinct
AGO proteins, human AGO1 through AGO4 seem to bind indiscriminately to microRNAs [32].
Functionally human AGO proteins appear to be equivalent. ES cells deficient for all four AGO
proteins lose microRNA silencing and undergoing apoptosis, with rescue from reintroduction
of any single AGO [33]. However only AGO2 is catalytically active and able to cleave bound
RNA molecules [34, 35] and there is evidence for some microRNAs and other small RNAs
being preferentially associated with distinct AGO proteins [36].
1.3 Small RNA processing
1.3.1 microRNAs
microRNAs are encoded within the genome as larger transcripts known as primary microRNAs
(pri-microRNAs), where they form hairpin loops in the RNA secondary structure (Fig 1.1a).
These structures are then processed in a series of steps first in the nucleus and then in the
cytoplasm to produce mature microRNAs incorporated into the RISC (Fig 1.1b).
Primary microRNAs (pri-microRNAs) are processed into precursor microRNAs (pre-
microRNAs) by the nuclear microprocessor complex containing Drosha and DGCR8 [37, 38].
Conserved in mammals and C. elegans Drosha is an RNase III enzyme capable of cleaving
pri-microRNA to release pre-microRNA in vitro [39]. DGCR8 (DiGeorge critical region 8,
also known as Pasha – partner of Drosha) is a double stranded RNA binding protein which
positions the Drosha cut site 11bp from the base of the hairpin stem, to release the ∼70nt
pre-microRNA[40].
While recognition of pre-microRNA hairpins by Drosha/DGCR8 remains to be fully
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elucidated, with many predicted microRNAs failing to produce mature microRNAs in vivo and
some loci with non-canonical stem base pairing patterns producing mature microRNAs[41],
key sequence and structural motifs have been identified: 40nt flanking either side of the
miR-223 pre-microRNA were seen to be necessary for processing in vitro[42]. Including an
∼11nt stem – or one turn of the RNA helix – flanking the pre-microRNA which determines
the cleavage site, and the single-stranded RNA regions flanking this are also critical for
processing[43].
Analysis of many variants of four human pri-microRNAs identified three sequence motifs seen
in Fig 1.1a: a basal UG present in 24% of human microRNAs, a UGUG motif in the terminal
loop present in 20% of human microRNAs and a 3’ CNNC motif present in 30% of human
microRNAs[45]. This CNNC motif was associated with SRp20/SRSF3 binding, a splicing
factor with an RNA recognition motif. Analysis of additional microRNA variants in a high
throughput assay revealed a preference for base-pairing in microRNA stems in all but one
position, although fully or near fully paired microRNA stems may have additional cellular
consequences in producing an interferon response, this study also confirmed the positive effect
on processing of the basal UG and apical UGUG motifs[46]. However ∼20% of human
microRNAs lacked all of these sequence motifs suggesting additional factors or recognition
features remain to be discovered. The RNA modification N6-methyladeosine (m6A) has also
been suggested as a mark recognised by DGCR8 to promote processing, deposited by the
methyltransferase-like 3 (METTL3) protein to GGAC motifs in the pri-microRNA[47]. It
should also be noted that all features defined to date relate to primary sequence or predicted
secondary structure, whereas processing is likely to occur in the context of three-dimensional
folding for which we currently have few measures or estimates.
Pre-microRNAs are exported to the cytoplasm via Exportin-5, a RanGTP dependent RNA
binding protein which traffics pre-microRNA through the nuclear envelope as an exportin
- RanGTP - cargo complex where the cargo and Ran are released in the cytoplasm after
GTP hydrolysis [48, 49]. In the cytoplasm pre-microRNAs are further cleaved by Dicer to
remove the hairpin loop. Knockdown of dicer in human cells leads to the accumulation of
pre-microRNA [50]. Dicer cleaves pre-microRNAs ∼22nt from the base of the ds-RNA stem
close to the terminal. Cleaved microRNAs are transferred to an AGO protein to form the
RNA-induced silencing complex (RISC) – the protein complex which represses target gene
expression[51]. The RISC is further mediated by several other proteins: In humans TRBP
(transactivation-response (TAR) RNA binding protein) a ds-RNA binding protein functions as
an asymmetry sensor [52] and the HSP70/HSP90 chaperone machinery is required to load
small RNA duplexes into argonaute proteins [53, 54]. microRNA duplexes are generally
classified as having a guide and a passenger strand. The guide strand is predominantly the
active strand and is incorporated into argonaute while the passenger strand is degraded [55, 51],
however passenger strands have also been seen to be incorporated into the RISC sometimes in
a tissue specific manner [56].
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(a)
(b)
Figure 1.1: (a) Annotated microRNA stem loop showing sequence motifs and RNA structural
features commonly found.
(b) - microRNA processing schematic showing nuclear processing by the microprocessor,
cytoplasmic processing by Dicer, and incorporation into Argonaute to form the mature RISC.
Adapted by permission from Macmillan Publishers Ltd: [Nature Reviews Molecular Cell
Biology] [44], copyright (2014)
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Pre-microRNAs may also be generated in a Drosha independent pathway as short introns
(Mirtrons) which are excised by the spliceosome [57, 58] and then exported to the nucleus
for further processing.
Another source of microRNAs are the transcriptional start site associated microRNAs
(TSS-microRNAs) observed in small RNA sequencing data[59] and immunoprecipitated
AGO protein complexes where enriched promoter proximal regions with bimodal peaks
corresponding to the 3p and 5p arms of a Dicer-processed product[60]. These TSS-microRNAs
were found at RNApolII paused regions and contained more structured transcripts compared
to control TSSs, though the functional significance of these TSS associated, dicer processed
transcripts remains unclear[61].
1.3.2 piRNAs
Single stranded RNA molecules are the precursors to piRNAs, as such they are Dicer
independent, transcribed in most species from clusters of piRNA genes producing precursor
transcripts from a few kb to 100kb in length[23]. However in C. elegans each piRNA is encoded
as a small transcriptional unit. Two main pathways for the biogenesis of piRNAs have been
observed. In the primary pathway precursor piRNAs transcribed from the genome undergo
processing at specific sites at the nuclear pores of germ cell nuclei where they are cleaved by a
nuclease enzyme to generate the 5’ end of the small RNA, this nuclease has been suggested to
be the Zucchini protein which in Drosophila mutants display primary biogenesis defects [62].
After generation of the 5’ end piRNAs are loaded onto PIWI proteins requiring chaperone
proteins, notably HSP90 or its orthologs [63]. piRNA lengths have a broad distribution,
the RNAs associated with different PIWI proteins having different length distributions. The
enzymes responsible for 3’ trimming to produce the final 3’ end are yet to be determined but
are followed by 2’OH methylation of the 3’ base protecting the piRNA from uridylation or
destabilisation [64, 65]. In the secondary piRNA pathway (sometimes referred to as ping-pong
amplification) cleavage of targets by piRNA generate the 5’ end of a new piRNA allowing an
adaptive response to target expression [66, 67].
piRNAs generally target transposable elements [68] during germline development where they
are expressed, although other target sequences have been observed including developmental
genes in Drosophila [69] and genes involved in the establishment of long term memory in
sea slug neurones[70]. PIWI proteins may silence their targets via RNA degradation [66, 67],
transcriptionally or post-transcriptionally. Transcriptional regulation has been suggested as
some PIWI homologs are observed in the nucleus after loading a piRNA and the PIWI
homologs MIWI and MILI2 are also localised to the nucleus where they lead to DNA
methylation of target loci [71, 72].
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1.3.3 Endogenous siRNAs
Another category of small RNA derived in a Dicer independent pathway are the endogenous
siRNAs (endo-siRNAs). These are produced by RNA-dependent RNA polymerases (RdRPs)
from cellular mRNAs, observed in C. elegans [73, 74] Drosophila [75, 76, 77] and mice [78,
79]. Derived from: transposable elements [78, 79]; cis-natural antisense transcripts (cis-NAT)
[79, 75, 77]; and trans-NATs derived from gene-pseudogene pairs [78, 79].
1.3.4 snoRNAs
In vertebrates snoRNAs are generally excised from the introns of pre-mRNAs although some
have their own promoter, and are generated through cleavage by exo- and endonucleases.
Divided into two main classes: C/D box snoRNAs bind the proteins of the small
ribonucleoprotein complex (snoRNP) including Fibrillarin, a methyltransferase that catalyses
the 2’-O-methylation of ribose in target RNAs. As with siRNA, microRNA and piRNA
targeting occurs through complementary base pairing. The snoRNAs contain conserved
complementarity to the universal core regions of rRNAs. H/ACA box snoRNAs bind proteins
to form snoRNPs which function in pseudouridylation of target sequences [80, 81]. Some
microRNA-like small RNAs can originate from snoRNAs, requiring Dicer for processing and
associating with AGO1 and AGO2 [82].
1.4 Targeting by Complementarity
After microRNAs were discovered as a large class of regulatory elements identifying their
targets became an important task. In plants this is less complex as extensive complementarity
can be used to predict interactions [83]. However in animals complementarity between a region
of the target and the whole length of the microRNA is not necessary to target the RISC and
algorithms to predict microRNA target sites were developed [84, 85, 86].
1.4.1 microRNA – Target evolution
Analysis of microRNAs and their targeting suggests that although some microRNA:target
relationships such as let-7:lin-41 persist over long evolutionary distances[4], overall
microRNA-target relationships appear to be conserved close to the level expected by chance,
with more rapid turnover than other regulatory mechanisms during evolution [87, 88]. Within
humans microRNA target sites appear to be under stronger negative selection than other
conserved sequence motifs in 3'UTRs[89].
One study identifying conserved microRNA response elements in human protein coding
3'UTRs found more than 45000 microRNA response elements in greater than 60% of
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genes[90].
A search for novel human microRNA genes uncovered miR-941 which evolved after the
separation of the human and chimpanzee lineages with variable precursor copy number in
the human genome. miR-941 was found to be expressed in a variety of tissues at high levels
including the brain, with targets suggesting roles in cellular differentiation. This was associated
with an accelerated loss of miR-941 binding sites in the human genome, presumably to escape
gene regulation by this newly evolved microRNA[91].
Collectively these results suggest that sequence conservation or its absence are of little
predictive value for microRNA identification or inferring microRNA-target interactions.
1.4.2 Computational Prediction
The algorithms initially developed to identify interactions utilised a number of features when
scoring a microRNA target sequence:
• Restricting searches to the 3'UTR of protein coding genes to reduce the search space[84].
• Watson-Crick pairing in the 5’ region of the microRNA around nucleotides 2-7 — the
seed region — were considered most important and searching for 7nt matches to the seed
region was generally the first step[92].
• Orthologous 3'UTRs compiled from whole genome alignments could then be used
to examine the evolutionary conservation of the Watson-Crick pairing of the seed
match[85].
• Regions of base-pairing in addition to the seed regions can be analysed to supplement
and strengthen the prediction or to compensate for lower seed pairing or conservation.
Changing parameters controlling the stringency of seed match necessary and the requirement
for evolutionary conservation or additional pairing allow for altering the sensitivity and
specificity of results. These predictions concluded that some — highly conserved —
microRNAs have a high number of conserved targets suggesting that more than half of
human protein coding genes appear to maintain microRNA target sites in their 3'UTRs[92].
Introduction of microRNAs into cell culture demonstrated modest effects on hundreds of
genes[93].
The incorporation of results from high throughput direct assays of microRNA-target
interactions has improved the target prediction algorithms[94, 95]. Analysis of CLASH derived
microRNA - mRNA pairs has been used in the development of TargetScan v7[96] which is
considered the current state-of-the-art in microRNA target prediction.
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1.4.3 Direct Assay
Methods to probe these small RNA interactions have benefited from the increasing availability
of DNA sequencing in order to probe these interactions genome-wide. CLIP (Cross
Linking and Immunoprecipitation) uses UV to crosslink proteins with RNA, followed by
immunoprecipitation for proteins of interest and cDNA sequencing. Chi et al performed HITS-
CLIP (high-throughput sequencing of RNA isolated by crosslinking and immunoprecipitation)
to examine AGO targeting in the mouse brain generating interaction maps for the 20 most
abundant microRNAs with the most abundant being miR-124, they also found 27% of AGO-
mRNA clusters had no predicted seed match among the top 20 most abundant AGO-microRNA
families [97]. Hafner et al used PAR-CLIP (photo-activatable ribonucleoside enhanced
crosslinking and immunoprecipitation) — a modification of CLIP which incorporates photo-
activatable nucleoside analogues into RNA and significantly improved RNA recovery — to
investigate a number of RNA binding proteins including AGO1-4 from HEK293 cells. They
found that 84% of binding sites were present within exonic regions – of those 4% to the 5'UTR,
50% to the coding sequence and 46% to the 3'UTR. Transfection of cells with a cocktail of
oligonucleotides to block the 25 most abundant microRNAs was performed to examine the
function of these targets. Genes with target sites exclusively within their coding sequence had
negligible effect compared to the upregulation of genes with targets sites within their 3'UTR.
The length of seed match had a noticeable effect on transcript abundance as targets with 9nt
seed matches showing the greatest upregulation after microRNA inhibition [98]. Leung et
al performed CLIP for AGO2 in mouse embryonic stem cells (mESCs) finding 201 enriched
motifs in 3'UTRs and 103 within coding sequence. They also found that different to other cell
types analysed a microRNA cluster – the miR-290-295 cluster appeared to be responsible for
the majority of targets [99].
Kudla et al observed during analysis of cross-linking and analysis of cDNAs (CRAC) of
the yeast RNA helicase Prp43 that some reads contained chimeric cDNAs with the guide
region of a snoRNA fused to a target site in the 18S rRNA, they hypothesised that during
the ligation of linker sequences in the CRAC procedure RNA molecules could be ligated
together. Computationally analysing the CRAC reads to identify these chimeric examples
found 0.46% of reads composed of distinct fragments which could be mapped to different RNA
molecules or different regions of the same molecule, this analysis was named cross-linking
ligation and Sequencing of Hybrids (CLASH) [100]. Application of the CLASH technique to
microRNA interactions (Fig 2.1) was performed via UV cross-linking and ligation, followed
by purification of PTH-AGO1 (N-terminal fusion of hAGO1) using six different experimental
conditions, and results from all six protocols were analysed together [101]. They found∼2% of
the total reads were chimeric with 70% of microRNA targets present within mRNAs, of these
5.5% were within 5'UTRs, 33.5% were within 3'UTRs and 61% were within coding sequence,
similar to results seen by CLIP methods. They also found a large class of chimeras with base
pairing only present at the 3’ end of the microRNA representing 18% of microRNA-mRNA
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interactions suggesting that previous CLIP and computational prediction of microRNA target
methods may have been biased towards finding interactions with Watson-Crick base pairing
within the seed region.
1.5 Mechanisms of regulation by microRNAs
1.5.1 Post-transcriptional regulation
The regulation of target mRNAs by microRNAs in animals are generally thought to occur at the
level of translation, whereas in plants they were though to act through target cleavage due to the
more extensive base pairing between microRNAs and their target sites in plants [1, 83, 102].
The mechanism of mRNA silencing by microRNAs occurs through a combination of
translational repression and mRNA destabilisation via decapping, deadenylation and 5’ to 3’
mRNA degradation, the relative contributions of these processes remains a research question
with evidence that both mRNA destabilisation[103, 104] or translational inhibition[105, 106]
cause the majority of this effect, although the processes may be linked[107].
Repression is mediated through the interactions of Argonaute, which forms the core of a
complex of proteins, including RNA helicases and mRNA binding proteins[108]. GW182
proteins, required for silencing, are a key component of this complex of proteins forming
interactions with cytoplasmic deadenylase complexes[109].
Mechanisms of translational repression by Argonaute have been reported to involve interactions
with the eIF4A RNA helicase proteins, which unwind mRNAs allowing the 43S pre-initiation
complexes to scan for the presence of the start codon[105, 106].
1.5.2 Transcriptional Gene regulation
It has now become clear that shortRNA directed gene regulation occurs at the levels of
translational repression and target degradation in both plants and animals[110, 103, 42, 111].
Cleavage of target mRNAs occurs through perfect complementarity between microRNA and
target, leading to cleavage by a catalytically active AGO protein [102]. Translational repression
of microRNA target sequences can occur at several stages during translation: The initiation
of translation can be blocked, seen though experiments using cell free extracts to compare
translation of native mRNAs to those with internal ribosome entry sites (IRES) [112, 113].
Post initiation mechanisms were suggested by the observation that microRNAs and their targets
were associated with polysomes in sucrose sedimentation gradients [114, 115]. A number
of different mechanisms have been suggested to contribute to post-initiation translational
repression including inhibition of elongation, co-translational degradation and premature
termination of translation [116].
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Increasing amounts of sequencing data have also increased our understanding of transcriptional
complexity. Sense-antisense transcripts have been observed with roles in gene expression in
many organisms including the production of endo-siRNAs [117, 118].
Nuclear functions for argonaute have been well observed in fungi and plants, and have
been suggested but are under explored in mammals[119, 120]. In the fission yeast
Schizosaccharomyces pombe deletion of the RNAi machinery resulted in the accumulation
of transcripts from centromeric heterochromatic repeats [121], and loci located within
heterochromatin regions displaying bidirectional transcription co-localised with Dicer1 at the
nuclear periphery favouring the production of endo-siRNAs [122].
In plants RNA has been shown to direct DNA methylation at specific, complementary
sequences. This was first observed using tobacco plants engineered to carry viroid identical
DNA sequences within their genomes which became methylated in strains carrying the actively
replicating viroid [123].
In the ciliate Tetrahymena a member of the PIWI subfamily is required for programmed DNA
elimination. This occurs in ciliates due to the presence of the germline micronucleus and
somatic macronucleus, during fertilisation DNA rearrangements and sequence specific DNA
elimination occur to leave the macronucleus lacking ∼15% of the DNA sequences present in
the zygotic nucleus or micronucleus. TWI1 (Tetrahymena PIWI1) is required for the formation
of viable progeny and knockout of TWI1 leads to loss of internal eliminated sequence (IES)
excision related to H3K9 methylation [124, 125].
The Drosophila PIWI homolog has been observed to have functions in the nucleus, associating
with heterochromatin protein 1 alpha (HP1a) [126] and loss of Drosophila PIWI leading to a
reduction of H3K9me3 at targeted loci [127, 128].
AGO proteins have also been associated with nuclear functions in Drosophila where AGO2 and
Dicer2 have been seen to associate with transcriptionally active loci and the core transcription
machinery. After heat shock null mutants for AGO2 and Dicer2 impair the global dynamics
of RNAPolII [129]. Moshkovich et al used AGO2 ChIP-seq finding it to be localised to
euchromatin and in particular co-localising with CTCF/CP190 chromatin insulators [130].
AGO2 is predominantly located within cytoplasmic processing bodies [131], however
AGO proteins as well as mature microRNAs have been observed in the nucleus via
immunoflourescence and cellular fractionation techniques [132, 133, 131, 134, 10, 135, 136].
1.5.3 shortRNA directed transcriptional gene regulation in mammals
Nuclear functions of AGO in transcriptional gene regulation have also been observed in
mammalian cells but remain controversial with some studies suggesting a repressive role, and
others suggesting an activating role for AGO in the nucleus.
CHAPTER 1. INTRODUCTION 13
Suggesting a repressive role siRNAs targeted to the promoter region of an EF1A promoter
– GFP reporter gene as well as endogenous EF1A finding silencing of both the reporter
and endogenous gene which was associated with DNA methylation of the targeted sequence
[137]. Short hairpin RNAs (shRNAs) complementary to the RASSF1A promoter were
observed to direct low levels of DNA methylation and partial gene silencing in HeLa
cells[138]. Transfection of HCT116 human colorectal cancer cell lines with double-stranded
oligonucleotides homologous to the CpG island of the CDH1 promoter found that CDH1
protein levels were repressed without a change in the level of DNA methylation [139]. siRNAs
induced a potent knockdown of 7SK small nuclear RNA (snRNA) in the nucleus [132]. siRNAs
targeting upstream of the transcription start site at the binding sites for transcription factors
reduce expression levels seen by nuclear run-on assay, this effect seemed to be dependant
on both AGO1 and AGO2 [140]. miR-320 encoded antisense within the promoter region of
POLR3D was able to direct AGO1, polycomb group component EZH2 and H3K27me3 to
the POLR3D promoter suggesting a cis-regulatory role at this locus directing transcriptional
gene silencing [141]. microRNA mimics, consisting of microRNA the sequence and a fully
complementary RNA carrier strand, predicted to target the progesterone receptor gene promoter
inhibit gene expression associated with decreased RNAPolII occupancy and increased H3K9
dimethylation [142]. Promoter profiling with ChIP-on-chip using an antibody targeting all
human AGO proteins in senescent and presenescent WI38 fibroblasts, found AGO2 associated
with the retinoblastoma (RB1)E2F repressor complex [143]. And suggesting an activating role
for AGO in the nucleus dsRNA targeting several gene promoters led to long-lasting sequence-
specific induction of the target genes, associated with a loss of H3K9 methylation [144], and
chromatin immunoprecipitation and sequencing (ChIP-seq) performed on HA-AGO1 and HA-
AGO2 expressed in PC3 – a human prostate cancer cell line to examine the distribution of AGO
proteins in the nucleus. Finding that AGO1 but not AGO2 was associated with the promoters
of actively transcribed genes [145]. Cell fractionation studies have shown that RNAi factors
and microRNAs are located in the nucleus and that siRNAs targeted to nuclear lncRNAs were
able to repress their targets[146]. A SILAC study demonstrated TSS proximal small RNAs
loaded into AGO2 associated with the SWI/SNF complex[147]. AGO2 was seen to associate
with the H3K9 methyltransferase SETDB1 suggesting a mechanism of chromatin remodelling
in TGS[148]. The formation of R-loops, where DNA and RNA strands base pair, form at
RNAPolII paused sites may also be a source of dsRNAs processed by DICER and loaded onto
AGO proteins[149].
1.5.4 Argonaute and small RNAs in splicing
Several studies have also implicated AGO proteins in affecting alternative splicing.
siRNAs targeted near an alternative exon were found to affect the alternative splicing at that
exon in HeLa and hepatoma cells, this effect being dependant on AGO1 and suggested to be due
to affecting the elongation rate of RNAPolII as the heterochromatin marks H3K9 dimethylation
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and H3K27 trimethylation were deposited at the target and the effect was reduced or abolished
in treatments which promote chromatin relaxation or an increased RNAPolII elongation rate
[150].
In mice AGO1 and AGO2 coimmunoprecipitated with the spliceosomal small nuclear RNP
(snRNP) U2 and U5 subunits, and using the CD44 gene as a model for alternative splicing as
it encodes a cluster of nine variant exons which display increased inclusion upon stimulation
of protein kinase C by the compound PMA, depletion of AGO1 or AGO2 compromised this
exon variant inclusion, reducing the recruitment of H3K9 trimethylation and slowing RNAPolII
progression [151]. In Drosophila Ago2 ChIP-seq found most peaks at gene promoters as well
as Ago-2-null mutants showing defects in pre-mRNA splicing patterns [152].
An AGO1 ChIP experiment demonstrated that in the nucleus AGO1 binds primarily at enhancer
regions, mediated by enhancer RNAs (eRNAs)[153]. However depletion of AGO1 led to
changes in constitutive and alternative splicing rather than transcription, this is suggested to
occur through changes in the chromatin marks present at gene loci, which in turn affect the rate
of RNAPolII elongation[153].
Models of the differences in splicing between MCF7 an MCF10 which including binding
sites of CTCF, AGO1, HP1 and chromatin marks were able to explain ∼69% of splicing
changes between the two cell types, with AGO1 binding clusters associated with CTCF and
HP1 binding sites[154].
1.5.5 Double-strand break associated small RNAs
Small RNAs are produced from regions of double strand breaks (DSBs) in human U2OS
(osteosarcoma) cells and Arabidopsis where they associate with Dicer or Dicer-like proteins
and AGO2, and knockdown of Dicer or AGO2 impairs the efficiency of DSB repair [155, 156].
AGO2 has also been seen to interact with Rad51, an interaction which is enhanced in the
presence of ionising radiation, with AGO2 suggested to promote the recruitment of Rad51 at
DSBs[157].
1.6 microRNA sequestration by competitive endogenous
RNA (ceRNA)
It has been hypothesised that competition between transcripts with shared microRNA binding
sites can affect the post transcriptional regulation of those microRNAs, with competing
transcripts including long non-coding RNAs (lncRNAs), pseudogenes and circular RNAs.
Large numbers of circular RNAs have been postulated or identified in human cells [158, 159,
160] with suggested roles acting as microRNA sponges due to observed high numbers of
microRNA binding sites, one example the cerebellar degeneration-related protein 1 transcript
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(CDR1as) containing 63 conserved binding sites for miR-7 and is densely bound by AGO in
PAR-CLIP datasets [160]. Circular RNA products from chromosomal translocations in cancer
have also been suggested to contribute to cellular transformation[161].
However the vast majority of circular RNAs did not demonstrate any selective constraint above
flanking exons or contain more microRNA target sites than would be expected by chance,
CDR1as being only one of two predicted circular RNAs with more microRNA target sites than
expected[162]. This result suggested that the vast majority of circular RNAs represent low
abundance alternatively spliced isoforms with debatable biological significance.
Several theoretical and practical studies have questioned whether ceRNAs will be likely to have
enough microRNA target sites, or be expressed at sufficient levels to influence target repression
by microRNAs: Altering the abundance of a validated miR-122 target in liver cells suggested
that a ceRNA must approach the normal target site abundance (1.5x105 for miR-122 in liver
cells) to affect target repression in a detectable manner[163]. Studies using predicted target
sites and reporter assays suggested that microRNA susceptibility to ceRNAs depends on the
relative microRNA:target ratio, with only those microRNAs with low microRNA:target ratios
being susceptible to ceRNA effects under normal circumstances[164, 165, 166, 167].
Additional examples of ceRNAs have been reported including: Hmga2 a non-histone
chromosomal protein with seven let-7 target sites in its 3'UTR, this activity important in
progression of non-small-cell lung cancer[168]. The BRAF pseudogene, acting as a ceRNA to
affect the expression of BRAF, which can act as a proto-oncogene[169]. Due to the intrinsic
sequence similarity of this gene/pseudogene pair these transcripts share many high affinity
microRNA target sites increasing the likelihood of ceRNA crosstalk. And Lin28B acting as a
ceRNA for let-7 in neuroblastoma cell lines leading to de-repression of MYCN, amplification
of which is associated with poor prognosis in neuroblastoma[170].
lncRNAs are an additional potential source of ceRNAs, one lncRNA knockdown study
suggesting that one fifth of transcript level changes induced by lncRNA knockdown were due to
microRNA mediated crosstalk[171]. Several other lncRNA microRNA sponges were predicted
computationally using AGO CLIP data[172].
1.7 microRNA polymorphisms
Polymorphisms at microRNA loci have the potential to impact their function in a number
of ways: Disruption of protein binding sites affecting microRNA processing. Disruption of
the RNA structure through changing base-pairing in the stem-loop, leading to less efficient
processing. Changes in the mature microRNAs may affect their incorporation into the
argonaute protein, or could change the targets recognised by the base-pairing of the microRNA
- particularly if the polymorphism is in the microRNA seed region.
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1.7.1 microRNA polymorphisms in the human population
Catalogues of polymorphisms in microRNAs and microRNA target sites have been generated
over the past decade:
• In 173 pre-microRNA regions in a cohort of 96 samples representing the general
population in Japan finding 10 SNPs in 10 pre-microRNAs[173].
• In 227 pre-microRNA regions in dbSNP finding 323 SNPs, 12 within the pre-
microRNAs including a SNP within the miR-125a mature microRNA which affected
the processing from pri-microRNA to pre-microRNA[174].
• In 474 pre-microRNAs in dbSNP and also in predicted target sites, finding 65 SNPs
in 49 pre-microRNAs, a lower SNP density (∼1.3 SNPs per kb) than flanking – often
intergenic – regions (∼3 SNPs per kb)[175].
• 15 SNPs were found within predicted microRNA target sites for 125 cancer associated
genes which altered the binding energy for the predicted interaction[176].
• Whole-genome sequences from 1092 individuals sequenced in the 1000 genomes project
and 60 exome sequences from healthy individuals in the south of Spain were used to
identify 527 SNPs including 45 within the microRNA seed regions[177].
Several databases have automated the collection and annotation of common SNPs in pre-
microRNAs and in predicted microRNA target sites[178, 179, 180, 181].
1.7.2 microRNA eQTLs
Using expression arrays or short RNA sequencing in populations of genotypically diverse cells,
associations between SNPs and the expression of microRNAs can be quantified. This is done
by correlating the SNP genotypes with gene expression patterns in order to identify expression
quantitative trait loci (eQTLs). These SNPs represent those which may affect the function of
microRNAs through altering their expression level - which could occur though affecting the
transcription, nuclear processing, cytoplasmic processing or stability of microRNAs. cis- or
local eQTLs have been defined as those within 50kb to 1MB of the target gene depending on
the study, with other associated SNPs being trans-eQTLs. It is expected some, but not all, cis-
eQTLs will be due to altered microRNA processing as variants can effect sequence or structural
recognition features.
• 180 primary fibroblasts were genotyped on Illumina Hap550 SNP array and had
expression profiling on the TaqMan microRNA Array V1 finding cis-eQTLs (within
1Mb) for 12 microRNAs[182].
• 70 samples of abdominal adipose tissue were genotyped on the Illumina BeadChip
317k and microRNA expression profiled with Illumina microRNA BeadArray finding
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6 independent cis-microRNA eQTLs[183].
• small RNA sequencing and genotyping of 131 samples of adipose tissue were used to find
14 cis-eQTL loci, 7 of which were also eQTLs for a mRNA transcript in the region[184].
• microRNA expression was quantified with the Exiqon miRCURY array in 60 European
and 60 African lymphoblastoid cell lines (LCLs) sequenced as part of the International
HapMap Project, finding 31 genome-wide significant SNP associations with microRNA
expression[185].
• small RNA sequencing in 363 European and 89 African individuals sequenced as part of
the 1000 genomes project found 60 microRNAs with cis-eQTLs[186].
Few studies have gone on to the next step to investigate the mechanisms by which identified
microRNA eQTLs effect expression level and none have done-so systematically for multiple
microRNAs or variants. Those which have been investigated are mainly SNPs or rare variants
identified as associated with diseases, particularly cancers, and will be discussed in the next
section.
1.7.3 microRNA polymorphisms in disease
microRNA variants may cause disease through their effects on microRNA function as
outlined above: altering transcription of the microRNA precursor, the biogenesis of the
mature microRNA from the precursor or by altering microRNA-target interactions. Case-
control studies have found evidence for associations between common microRNA variants and
diseases, particularly in cancer and in some neurodevelopmental disorders.
A variety of microRNA expression profiling and genome-wide association studies have
associated microRNA expression signatures and common polymorphisms at microRNA loci
with a number of diseases, particularly cancers.
Observed associations include rs7372209 in miR-26a with decreased risk of bladder cancer in
females[187] and rs11614913 in miR-196a with increased risk of breast cancer[188]. Levels
of the microRNA processing machinery has also been associated with cancer. Dicer and
Drosha were found to be decreased in ovarian cancer, with higher expression associated with
increased median survival[189]. Expression profiles of microRNA genes have also been used
as a biomarker to classify cancers with some prognostic utility[190].
Neurodevelopmental disorders have also been associated with microRNAs. Genome-
wide association studies have identified miR-137 and SNPs near miR-137 target sites in
schizophrenia[191]. Variants in miR-182 have also been suggested to affect major depression
and insomnia through regulation of the circadian clock modulator (CLOCK gene) by miR-
182[192].
A heterozygous deletion of the microRNA-17-92 cluster was found in a patient with
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Feingold syndrome – a rare autosomal dominant disorder characterised by microcephaly, short
stature and digital abnormalities – with targeted deletion of this microRNA cluster in mice
phenocopying several features of the disease[193]. This microRNA cluster is hypothesised to
be a downstream effector of MYCN, with loss of function mutations in MYCN responsible for
over two thirds of Feingold syndrome cases[193].
1.7.4 Disease associated variants affecting microRNA expression
There are several examples of human disease associated or implicated variants that have been
shown to impact microRNA expression:
A germ-line pri-microRNA mutant 7bp downstream of the miR-16 pre-microRNA was seen in
two patients with chronic lymphocytic leukaemia (CLL), low levels of this microRNA having
been identified as associated with CLL. Pri-microRNA constructs with this mutation expressed
the microRNA at significantly lower levels than wild type[194] though the mechanistic basis
for that difference in expression has not been demonstrated.
A common SNP rs2910164 within the miR-146a pre-microRNA associated with colorectal
cancer risk (OR:1.34 95% CI 1.15-1.67) and survival (Hazard Ratio 2.12)[195] and breast
cancer risk (OR:1.77, 95% CI 1.40-2.24)[196] was found through microRNA processing assays
to reduce the level of pre-microRNA produced from the primary transcript during nuclear
processing leading to a reduced level of mature microRNA[197].
A rare novel variant within the terminal loop of the miR-30c-1 pre-microRNA in a non-
BRCA1/BRCA2 mutant breast cancer patient was predicted to alter the secondary structure
of the precursor. This variant was found to increase the levels of the mature microRNA,
a predicted regulator of BRCA1[198]. Investigation of the mechanism of this effect by the
Caceres’ lab (Edinburgh) found that the variant affected processing by the microprocessor
complex. The effect of this variant on the RNA structure of the primary microRNA was
then assayed using two complementary methods: Selective 2’-hydroxyl acylation analysed by
primer extension (SHAPE), able to distinguish single stranded base-pairs which are highly
reactive, from double stranded base-pairs which are non-reactive. And hydroxyl radical
cleavage footprinting assaying the solvent accessibility of each nucleotide from the effect of
hydroxyl radicals which break the RNA backbone in accessible regions. Combining these
analyses they found that the variant present in the terminal loop caused a conformational
change in the pri-microRNA, modifying the base pairing in both their terminal loop and in the
basal stem. Assaying the effect of the variant on protein binding to the pri-microRNA through
RNase-assisted chromatography followed by mass spectroscopy they found the variant led to
binding of SRSF3, a factor previously described in microRNA biogenesis as binding to the
CNNC motif downstream of the hairpin. Further validation trough SRSF3 overexpression and
mutations of the CNNC motif confirmed that this interaction of SRSF3 at the CNNC motif was
affected by the RNA structure changes caused by this variant in the terminal loop[199].
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microRNA mutants have also been seen to cause a Mendelian developmental disorder. Separate
mutations at adjacent base-pairs in the seed region of miR-96 were identified in two families
as segregating with autosomal dominant deafness[200]. This microRNA is expressed in
the inner ear, necessary for the maturation of the hair cells which transduce sounds into
electrical stimuli[201]. Both of these mutants present in the seed region and therefore affecting
microRNA targeting were also seen to affect microRNA biogenesis, with both mutations
leading to an ∼80% decrease in expression of the mature microRNA[200].
1.8 Aims
Through this introduction I have highlighted the importance of microRNAs in the regulation
of gene expression (Section 1.5), detailed the molecular steps in the biogenesis of microRNA
(Section 1.3.1) and demonstrated that genetic variation affecting microRNA regulation can lead
to human disease (Section 1.7.3).
Despite these insights, it is apparent that our understanding of microRNA mediated regulation
is incomplete. Argonaute proteins are abundant in the nucleus and have clearly defined roles
in the nucleus of plants (Section 1.5.3) but their roles and targets in human nuclei are not well
defined.
The determinants of microRNA targeting, though clearly based in part on complimentary base-
pairing are not fully understood so cannot be well predicted (Section 1.4.2). Similarly the
consequences of sequence changes in the mature microRNA or its precursor cannot currently
be predicted either in terms of processing efficiency or alterations in target specification
(Section 1.7.2).
The work presented in this thesis sets out to use integrated genome-wide measures of
microRNA-target interactions and expression data to systematically explore the nature of the
microRNA mediated targeting of Argonaute, their sequence and context determinants and to
understand how sequence changes to microRNA and their precursors can disrupt either the
targeting or biogenesis of microRNAs. The specific aims that I will seek to address are:
• To use CLASH data to examine the genome-wide distribution of Argonaute targeting,
identifying enrichment of microRNA targets amongst the transcriptome. Also examining
the evidence for Argonaute targeting within the nucleus affecting transcription or
splicing, and modelling microRNA targets genome-wide to examine the evidence for
competitive endogenous RNAs.
• To examine the factors which contribute to microRNA processing using polymorphisms
in human population. In both normal samples where these microRNA eQTLs can be
identified in available genome sequencing and small RNA expression data. And in
disease samples through exome and genome screening to determine if polymorphisms
at microRNA loci contribute to disease phenotypes.
Chapter 2
Methods
This chapter describes datasets and software used in the following chapters, each subsequent
chapter also describes in more detail the specific application of these methods.
2.1 Datasets
2.1.1 CLASH data
Nine independent cross-linking ligation and Sequencing of Hybrids (CLASH) datasets from
Helwak et al[101] performed with slightly differing protocols are used to examine microRNA
targeting in chapters 4 and 5.
In these CLASH experiments (schematic in Fig 2.1) HEK293 cells stably expressing N-
terminally His tagged AGO1 proteins were UV irradiated to crosslink proteins with interacting
RNAs. Tagged AGO1 proteins were purified and interacting RNAs were partially hydrolysed,
ligated, reverse transcribed and sequenced. A subset of these sequenced reads (2-10% in
the differing protocol variations) are hybrid reads representing intermolecular RNA–RNA
interactions.
2.1.2 RNAseq datasets
Whole-cell and cell fractionated nuclear and cytosolic data were generated for this project and
other Taylor lab projects, processing and analysis of this data are described in chapter 4, as well
as its use in normalising for transcript abundance.
Whole-cell and cell fractionated nuclear and cytosolic data in five different cell lines from
the ENCODE consortium[203] are compared with the generated HEK whole cell and cell
fractionated data.
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Figure 2.1: Schematic of the CLASH method showing purification, ligation and sequencing of
protein bound RNA-RNA molecules. Applied to Argonaute protein a microRNA is shown in
red, target RNA in blue.
Adapted from Travis et al.[202] licensed under CC BY 3.0.
2.1.3 eQTL datasets
Genome-wide DNA sequences from the 1000genomes project[204] and shortRNA sequencing
performed in cell lines from the 1000genomes project by the GEUVADIS consortium[186] are
used to identify microRNA eQTLs in chapter 6.
2.1.4 Patient exome data
A variant database from exome sequencing and variant calling of 1295 patients or parental
controls from five patient cohorts within the IGMM are analysed in chapter 7 examining
variants at microRNA loci.
2.1.5 Other resources
• All alignments and annotations are made to the GRCh37 genome assembly.
• GENCODE[205] v19 annotations are used throughout
• RepeatMasker[206] v3.3.0 (2012/01/24 hg19 annotations) are used in chapter 4
• miRBase[11] v20/v21 microRNA annotations are used throughout.
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• FANTOM5[207] transcription start site annotations are used in chapter 4.
• Predicted circular RNAs from Memczak et al[160] are used in chapter 4.
• SNPs from dbSNP[208] v139 and ExAC[209] release 0.3 variants are used for
comparison throughout.
• DECODE[210] derived allele frequencies are used to test for selection in chapter 6.
• TargetScan[96] v7 predicted microRNA targets are used in chapter 7.
2.2 Software
hyb[202], a pipeline developed with collaborators for the identification of hybrid sequence
reads and applied to CLASH data is described in chapter 3 and is available at
https://github.com/gkudla/hyb.
I have also developed hyb gen, an extended hybrid read identification pipeline for alignment
and analysis genome-wide, described in chapter 3.
2.2.1 Programs
The following programs have been used in this thesis:
• Bowtie2[211] v2.1.0: genome alignment
• Tophat2[212] v2.0.10: Splice aware aligner
• blastn[213] v2.2.26: aligner
• UNAfold[214] v3.8: RNA folding energy calculation
• STAR[215] v2.4.2a: Splice aware aligner
• Kallisto[216] v0.42.3: Transcript quantification
• DEseq2[217]: Quantification normalisation
• sleuth[216]: Quantification normalisation
• BEDTools[218] v2.21.0-26: Operations on genomic intervals
• BCFtools[219] v1.2-5: Operations on variant data
• H3M2[220]: Copy number analysis in exome data
• Forgi v0.2: An RNA manipulation python package
(http://www.tbi.univie.ac.at/∼pkerp/forgi/)
• python v2.7.1: Numerous custom scripts were written in python
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• R[221] v3.2.2: Datasets were analysed and graphed using R and the packages below
2.2.2 R packages
• ggplot2[222] v2.1.0: Graphs
• data.table[223] v1.9.7: Data manipulation
• MatrixeQTL[224] v2.1.1: eQTL testing
• VennDiagram v1.6.16: Venn diagrams
• gplots v2.17.0: for heatmap.2 function
• party[225] v1.0-25: cforest function for random forest implementation.
Chapter 3
Hybrid read mapping pipeline
3.1 Introduction
Inter-molecular RNA–RNA interactions are key to many cellular processes including; pre-
mRNA splicing where spliceosomal RNAs bind to splice site motifs, ribosome synthesis where
snoRNAs guide the modification of other RNA molecules, translation where tRNA molecules
base pair with complementary mRNA codons, and the activity of microRNAs, which bind to
other RNA molecules in the cell through complementary base pairing (section 1.4), leading to
the suppression of protein translation from a target mRNA or facilitating the degradation of the
target (section 1.5).
A number of methods have been developed to assay microRNA targets in cells, generally
extensions of the CLIP protocol where UV exposure is used to crosslink proteins with RNA,
proteins of interest can selected for, and pools of RNA can be further processed and sequenced
in high-throughput (section 1.4.3).
The CLASH protocol[100] is one extension of CLIP where after selection for the protein
of interest an RNA ligation reaction is performed. Applying this to Argonaute attempts to
ligate the microRNAs bound by Argonaute to their target RNA molecule. The pool of RNA
molecules sequenced will then contain some fraction of hybrids, one part microRNA and
one part target. The identification of these hybrid RNA sequence reads and resolution of the
component interaction partners is then a computational problem to be addressed.
One solution to this hybrid read mapping problem was applied by Helwak et al. to the
first CLASH experiments identifying 18,500 microRNA-mRNA interactions[101]. In a
collaboration with the authors of that original solution, I have tested, revised, and produced
a revised pipeline as a standalone package named hyb[202]. Specifically I have implemented:
alignments using Bowtie2, a substantial improvement in speed over previous versions using
blastn. Tested the hyb package against Tophat2-fusion[226] a popular method designed for
calling gene fusions with hybrid reads. Tested and debugged the standalone package for bugs
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and improvements to usability.
A limitation of the hyb based mapping approach and other previously developed
microRNA:target mappers was that they assumed the targets were annotated transcripts.
As much of the genome is known to be transcribed[227] and Argonaute mediates RNA
interactions in the nucleus as well as the cytoplasm (section 1.5) there is a strong rationale for
the development of a genome wide CLASH mapping algorithm that can explore the possibility
of non-canonical Argonaute mediated interactions and also for the unbiased investigation of
all microRNA interactions in less well studied transcriptomes (cell types, cancer genomes or
species) where there is a genome sequence or appropriate reference available.
Building on hyb I have developed a separate pipeline using genome-wide mapping to
investigate the diversity and distribution of microRNA targets, this creates some additional
challenges including accounting for multi-copy and highly repetitive sequences and the
separation of transcripts into exons. This pipeline has been used in chapters 4 and 5.
3.2 hyb - development and testing
The original version of hyb was developed by Grzegorz Kudla for the analysis of CLASH data,
the outline of the hyb pipeline is shown in Fig 3.1. It used the local alignment of reads to
a transcriptome database with blastn[213], these alignments were then processed to identify
hybrid reads. Where non-end-to-end alignments are found hybrids were identified through an
iterative process starting with the top scoring match comparing each additional alignment in
score order for whether they map the remaining portion of the read allowing a gap or overlap of
4bp. Where there were multiple hybrids possible the selection criteria were: 1) the sum of the
alignment scores for both fragments of the chimera. 2) The transcript classes of the chimera
favouring microRNA-mRNA hybrids. 3) The transcripts with the highest total number of reads.
Features which were identified to be improved on from this original version for the publication
of a standalone package were the run-time, changing the aligner to make use of read quality,
and incorporating the option for a genomic alignment.
3.2.1 Bowtie2 alignment
Alignments in hyb were initially performed with blastn[213], which while allowing sensitive
alignment of read fragments was time consuming for large datasets and was not able to take
advantage of the FASTQ read quality information.
Bowtie2[211] a popular alignment tool for next generation sequencing data has an option
for local alignment, allowing fragments of reads to be aligned rather than whole reads being
aligned end-to-end as in the original Bowtie.














list of RNA-RNA interactions
Figure 3.1: Steps performed by the hyb analysis pipeline
Adapted from Travis et al.[202] licensed under CC BY 3.0.
Using a list of reads which had been identified as hybrid reads after blastn alignment and
processing using an e-value threshold of 0.1 with all other parameters default, I determined via
trial and error a set of Bowtie2 parameters to approximately reproduce these results using the
built in --very-sensitive parameter set to control the number of seed extension attempts
with a smaller seed length (16bp) reporting alignments with a minimum score of 18.
Applied to the ’E4’ CLASH dataset, ∼34 million reads from one variation of the CLASH
protocol performed by Helwak et al[101], mapped to a custom transcriptome database using
Bowtie2 v2.1.0[211] and blastn v2.2.26[213] identified similar numbers of hybrids: 14019
in common, 3313 only in blastn and 2711 only with Bowtie2. In the absence of a complete
set of known interactions it would be useful to have some orthogonal measure of sensitivity
and specificity for the prediction of these interactions. One such measure that has been used
previously is that of folding energy[228]. More negative folding energies between microRNA
and target indicate greater nucleotide complementarity and stability of a hydrogen-bonded
duplex of the RNA molecules, thought to be an important component of the interaction between
microRNA and target. Hybrids identified following alignments with both programs both had
the same folding energy distribution with median value ∼-18kcal/mol. However the run time
with Bowtie2 was ∼1 hour, instead of ∼11 hours with blastn.
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3.2.2 Tophat2 fusion-search comparison
As a comparison to an existing method hyb was compared with the Tophat2 v2.0.10 fusion-
search option[212], developed for the identification of fusion transcripts in cancer. This is
a solution to a similar problem based initially on finding reads with segments aligning to
different transcripts or to different genomic locations. Tophat2 fusion-search uses a multi stage
process where reads are first mapped end-to-end, unmapped reads are then cut into fixed width
segments and each aligned end-to-end, those segments from the same read which aligned on
separate chromosomes or greater than 100kb apart are then used to form ’fusion contigs’ which
the initially unmapped reads are aligned to. Read coverage filters can then be applied to define
fusion events.
The parameters for Tophat2 fusion-search had to be modified to allow the identification of
short microRNA segments, and to not impose a read coverage threshold. The results of both
pipelines were compared for; the number of microRNA hybrids identified, and the folding
energy measuring how well the two RNA fragments base pair calculated with hybrid-min from
the UNAfold v3.8[214].
With optimised parameters for both Tophat2 v2.0.10 fusion-search and the updated hyb,
Tophat2 fusion-search identified 8231 microRNA:mRNA hybrids and hyb identified 13483.
This raises the question as to whether hyb is over-predicting or Tophat2 fusion-search is under-
predicting interactions.
As neither hyb nor Tophat2 fusion-search makes use of folding energy in their identification
of hybrids, this can be used to estimate the relative enrichment of genuine Argonaut mediated
microRNA:target interactions[94]. Tophat2 fusion-search microRNA-mRNA hybrids had a
mean folding energy of -10.3kcal/mol, whereas the hyb identified microRNA-mRNA hybrids
had a mean folding energy of -18.2kcal/mol, the distribution of these folding energies is shown
in Fig 3.2 compared to a shuffled dataset where microRNA-mRNA pairs are randomised.
This suggests that Tophat2 fusion-search misidentified many hybrids, possibly due to the fixed
with segments of reads which are aligned to produce the ’fusion contigs’ rather than the local
alignments used by hyb.
3.2.3 Usability and testing
hyb is implemented as a makefile calling additional programs and supplied scripts to generate
the desired outputs. Combinations of varying types of input file and processing options
were tested to ensure expected results, useful help and error messages, and specification of
prerequisites.
I have published hyb as a standalone pipeline with my collaborators [202], it is publicly
available at https://github.com/gkudla/hyb distributed under the GNU GPL (General Public
License).
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Figure 3.2: Comparison of hyb and Tophat2-fusion in the identification of hybrid sequence
reads. Distribution of folding energies of microRNA-mRNA chimeras recovered with hyb,
Tophat2 fusion-search, and in randomly re-associated microRNA-mRNA pairs from the
Tophat2 fusion-search analysis. More negative dG values represent stronger base-pairing.
3.3 Genome-Wide mapping pipeline
I have created an alternative hybrid mapping pipeline using alignment to a reference genome,
this has the advantage of ensuring that reads are aligned to their best match regardless of
transcript type, allowing analysis of their genome-wide distribution. Some aspects of this
such as using Bowtie2[211] for fast local alignment have since been incorporated into the hyb
package.
3.3.1 Overview of the pipeline
After trimming sequencing adaptors, reads are aligned to the genome using Bowtie2 local
alignment as described previously (section 3.2.1), the resulting sam file is then processed to
identify hybrids based on a set of criteria:
• Reads must not align to more than m locations in the genome above an alignment
threshold n. Highly repetitive sequences which cannot be uniquely mapped are of limited
use in downstream analysis and will require excessive memory and processor use to
calculate all such mapping locations and examine them for hybrid pairs. Limiting this
parameter will substantially improve performance.
• If the best scoring alignment does not cover the whole read, pairs of alignments are
considered to identify if any two have a higher alignment score than the best single
alignment, these are the candidate hybrid reads.
• To be considered a hybrid read the pair of alignments must cover more than 80% of the
read length. This allows for some unmapped bases due to insufficient linker trimming,
but ensures source of the read is a single hybrid of two RNA molecules.
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• The pair of alignments must also not have a gap or overlap >p bases. A gap/overlap will
allow for ambiguous edges, where the alignments may by chance extend into the partner.
If reads can be assigned to more than one hybrid with the same alignment scores they are
assigned to the hybrid with the highest number of non-hybrid reads calculated by summing
the non-hybrid reads which overlap each potential hybrid. Such that hybrids with ambiguous
alignments are assigned to the alignment with the most supporting evidence (a rich get richer
strategy).
The final list of unambiguous hybrids (one read: one hybrid) are then be collapsed using a
custom python script such that 10 reads hybrid for locusA-locusB will appear once with a
count of 10. These lists are then be intersected with regions of interest using tools such as
BedTools [218] and the folding energy between the RNAs of each hybrid can be calculated
using UNAfold [214] or the Vienna package[229].
3.4 Parameter sweep
A parameter sweep was performed for this pipeline, running the pipeline multiple times on
the same dataset with a range of parameters to identify optimal values based on a scoring
criteria. The E4 dataset of Helwak et al.[101] was used, varying the alignment score threshold
(16,17,18,19,20) and the hybrid calling parameters: maximum number of alignments per read
(5,10,20), and allowed gap/overlap between the alignments (0,1,2,3,4,5,6). Performance was
measured by:
• The number of microRNA containing hybrids identified, to be maximised as these are
the primary data for downstream analysis.
• The mean folding energy of those microRNA hybrids as calculated by UNAfold
v3.8[214], this score is to be minimised, where lower folding energy corresponds to
higher complementarity between microRNAs and their targets. As no true positive set of
hybrids is known this orthogonal score not used in the generation of hybrids is used as a
proxy for their sensitivity/specificity.
• The number of mRNA-mRNA hybrids identified which correspond to true splice
variants, identified as reads which align to an mRNA transcriptome database but as
hybrids when aligning to the genomic database. These are a different set of hybrid read
expected to be present in the database when using a genomic alignment. This is to be
maximised as in this case a set of true hybrids is known, although mRNA-mRNA hybrids
may have different properties to microRNA-mRNA hybrids.
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3.4.1 Results
Fig 3.3 shows the results of this parameter sweep. Optimum parameters were selected based
on maximizing the number of microRNA-mRNA hybrids called and true exon-exon splice
variants while minimizing the mean folding energy of the microRNA-mRNA hybrids. Relaxing
thresholds lead to identifying more hybrids but with a lower mean folding energy. Parameters
selected to identify hybrids for use in chapters 4 and 5 were alignment score 19, gap/overlap
4 and alignments per read 10. These parameters may be easily configured by the user for
application of the pipeline in different contexts, e.g. with longer sequencing reads.
3.5 Chapter summary
I have published a pipeline - hyb - for the identification of hybrid sequencing reads[202].
Developed for the analysis of CLASH data it has been extended, tested against a popular fusion
mapping program and made freely available online.
I have also created a pipeline for the analysis of CLASH data genome-wide. Some aspects of
this pipeline such as the use of Bowtie2[211] local alignment allowing genome wide alignment
within a reasonable time frame for large datasets have subsequently been incorporated into
the hyb pipeline. This genome-wide hybrid mapping pipeline was optimised to identify
microRNA-mRNA hybrids and exon-exon junctions in a CLASH dataset while maintaining
a low minimum free energy in the folding of the microRNA-mRNA hybrids.
Applying this pipeline to AGO1 CLASH data allows the analysis of small RNA-mediated
RNA–RNA interactions identifying both segments. These hybrids will be analysed in the
following chapters; chapter 4 examining the genome-wide distribution of hybrids and their
enrichments in classes of transcripts, and chapter 5 examining clusters of hybrid targets
corresponding to sites of high occupancy including competitive endogenous RNAs.
This pipeline has also been applied in other projects at the IGMM, being used to identify
genomic rearrangements at specific loci in whole-genome sequencing data[230].
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Figure 3.3: Results of parameter sweep. (x-axis both) mean folding energy of microRNA-
mRNA hybrids. (y-axis a) number of microRNA-mRNA hybrids. (y-axis b) number
of recovered exon-exon junctions. (panel number) alignment score threshold. (colour)
gap/overlap threshold. (shape) alignments per read threshold. Ideal results would be towards




In the post-transcriptional regulation of protein coding genes by microRNAs, microRNAs
as part of the RISC complex bind to the 3'UTRs of protein coding genes leading to their
translational repression or cleavage (section 1.5). However a number of studies have identified
microRNA targets within exons and lincRNAs hypothesised to act as competitive endogenous
RNAs limiting the amount of microRNAs free to repress their gene targets[159, 160, 161]
(section 1.6). Studies have also suggested microRNA targeting in the promoter or internal
exonic regions with hypothesised roles in transcription[137, 231, 139, 132, 144, 147, 141]
(section 1.5.3) or splicing[154, 153, 151, 150] (section 1.5.4).
In this chapter AGO1 mediated RNA–RNA interactions are identified in all 9 CLASH datasets
from Helwak et al[101] using the genome-wide hybrid mapping pipeline discussed in chapter 3.
These RNA–RNA interactions are analysed for the distribution and specificity of microRNA
targeting.
One important factor in analysing the distribution and specificity of microRNA targets is
transcript expression level in assessing target specificity and location, as hypothesised effects
on transcription or splicing must occur within the nucleus.
In order to address this I have used cell-fractionated cell-matched RNA-seq to provide estimates
of transcript abundance and sub-cellular localisation. This allows me to test the widely held
hypothesis that microRNAs primarily target the 3'UTR of protein coding transcripts and that
these interactions occur primarily in the cytoplasm.
32
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4.2 Methods
4.2.1 Datasets
Nine independent cross-linking ligation and Sequencing of Hybrids (CLASH - protocol
described ) datasets from Helwak et al[101] performed with slightly differing protocols were
used in this analysis (section 2.1.1).
RNAseq in whole cell and cell fractionated (nuclear/cytosolic) HEK293 cells was
commissioned for use in this project and other Taylor lab projects. HEK293 cells from IGMM
stocks were maintained in DMEM supplemented with 10% fetal calf serum and tested negative
for mycoplasma contamination. Cell fractionation and sequencing was performed for two cell
culture replicates with each fraction spread over multiple lanes allowing for the detection and
correction of various batch effects.
4.2.2 Mapping with genomic hyb
Mapping single and hybrid reads was performed with the genomic hyb pipeline discussed
in chapter 3, using the default parameters selected by the parameter sweep for optimal
performance in whole mammalian genome alignment.
4.2.3 Annotation
Hybrid read segments were annotated by intersection with a bed file comprised of miRBase
v21[11] mature microRNAs, repeatmasker[206], Gencode v19[205], and manual annotations
of rDNA loci. An annotation hierarchy was used where multiple annotations overlapped a
hybrid read segment in the order of: rDNA, microRNAs, repeat loci, gene 3'UTR, gene 5'UTR,
gene exon, gene intron.
Folding energy
The folding energy between the hybrid segments was calculated using hybrid-min from the
UNAfold v3.8[214] package, as a measure of how well the RNA molecules base-pair together.
RNAseq quantification
In order to normalise to RNA expression level, RNA sequencing data to high depth from
HEK293 cells was commissioned and analysed. Consisting of Whole cell and cell fractionated
(nuclear / cytosolic) each with two biological replicates spread across 6 lanes of sequencing
giving 36 fastq files per sample. Alignment was performed with STAR v2.4.2a[215]
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with parameters used by the ENCODE project[203], which also output read counts for
Gencode transcripts. Read counts were analysed with DEseq2[217] performing library size
normalisation and tests of differential expression.
Transcript quantification was also performed with the alignment free program Kallisto
v0.42.3[216], these results were compared to quantifications after STAR alignment to verify
the alignment free approach in this and future projects. Transcript quantification with Kallisto
v0.42.3[216] was also performed in the same way for five cell types from the ENCODE
project[203] with similar whole cell and nuclear/cytosolic cell fractionated data.
Transcripts and genes are then quantified using TPM - transcripts per million, interpreted
as if you were to sequence 1 million full length transcripts from a sample, the number of
transcripts of one type seen is given by its TPM. This measure proportional to RPKM/FPKM
within an experiment is more consistent between experiments[232]. Quantifications were
made to an index comprised of the protein-coding and long non-coding RNA transcripts from
Gencode v19[205]. Quantifications were normalised for library size using the sleuth prep
and kallisto table functions from the sleuth R package[216].
These transcript quantifications are used in this project and other Taylor lab projects.
Statistical modelling
Linear models were used to examine the influence of transcript expression level on CLASH
targeting by performing regression with second order polynomials using the R functions lm
and poly from the stats package.
A random forest[233] algorithm based on conditional inference trees using the R function
cforest[225] from the party[225] v1.0-25 package and a variable importance measure using
the R function varimpAUC[234] also from the party[225] v1.0-25 package were used to build
models for and estimate the importance of different predictors in predicting CLASH targeting.
Statistical tests
Enrichment analyses for microRNAs targeting specific locations were performed with Fisher’s
exact tests using the R function fisher.text from the stats package.
4.3 Results
4.3.1 RNAseq quantification
Table 4.1 shows the RNA-seq sample information for the commissioned cell fractionated HEK
samples. Each sample replicate was run in triplicate split across six lanes of two sequencing
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run lane replicate cytosol nucleus whole.cell
110 1 1 3 3 3
110 1 2 3 3 3
110 2 1 3 3 3
110 2 2 3 3 3
257 5 1 3 3 3
257 5 2 3 3 3
257 6 1 3 3 3
257 6 2 3 3 3
257 7 1 3 3 3
257 7 2 3 3 3
257 8 1 3 3 3
257 8 2 3 3 3
Table 4.1: HEK293 RNAseq experimental design: number of cytosolic, nuclear and whole cell
samples in each sequencing run, lane, and culture replicate
runs. Each of the 18 samples run for each replicate had between 8.5 million and 19.2 million
reads (median 13 million), giving sample a combined number of reads between 211 million
and 270 million (median 259 million). This experimental setup allows for the detection and
correction of various batch effects.
After alignment with STAR[215] v2.4.2a the HEK samples had median 91% reads uniquely
mapping, with the ENCODE[203] samples having median 88% reads uniquely mapping. The
proportion of reads aligning to constitutive exons and introns was calculated for both the HEK
and five ENCODE cell type datasets, the results shown in Fig 4.1. These suggest that the
HEK fractionation was successful with exonic fragments highest in the cytosol and lowest in
the nucleus, and the reciprocal result for intronic fragments. Compared with the ENCODE
cell types, the proportions of reads in the whole cell fraction seem broadly similar, in the
cytosol fraction they are again broadly similar with the HEK data having very few intronic reads
due to little nuclear contamination, the nuclear fraction seems somewhat different with more
exonic and fewer intronic reads than the ENCODE cell types suggesting some cytoplasmic
contamination. These differences between the HEK and ENCODE cell types will likely reflect
that different cell fractionation protocols were used to generate them.
Recently alignment free methods for RNAseq quantification have become more popular due
to their speed and proposed accuracy. I have processed the same HEK RNAseq datasets using
the alignment free method Kallisto[216] v0.42.3. Fig 4.2 shows comparisons for estimated
fragment counts from Kallisto and actual fragment counts from STAR[215] v2.4.2a, with
spearman rank r2 values greater than 0.95 in all three cellular fractions. Length normalised
estimated fragment counts from Kallisto (TPM - transcripts per million) were used for
transcript normalisation in this chapter.
Examining the overlap in expression levels in the cellular fractions in Fig 4.3, the numbers of
genes expressed with TPM >1 and their overlaps are broadly similar between the cell types,































































































































Figure 4.1: RNAseq fragments aligning to (a) exonic or (b) intronic regions. For different cell
types, 5 from ENCODE and HEK293. Replicates are shown with differing shades of grey.
Values indicate the success of the cell fractionation protocols.
(a) Whole cell r2=0.952 (b) Cytosol r2=0.964 (c) Nucleus r2=0.960
Figure 4.2: Estimated fragment counts from the alignment free method Kallisto[216] v0.42.3
and STAR[215] v2.4.2a alignment. Spearman rank r2 values shown.





























































Figure 4.3: Venn diagrams displaying the numbers of genes expressed >1 TPM in the whole
cell, cytosol, and nuclear fractions for the six different cell types. Five from ENCODE and the
generated HEK data.
with fewer genes in the HEK cells fewer nucleus specific genes and more cytosol specific genes.
As TPM is based on the relative proportion of transcripts in the sample this difference in the
HEK cells may be due to additional non-nuclear transcripts contaminating the HEK sample,
and fewer non-cytosolic transcripts contaminating the cytosolic fraction.






































Figure 4.4: Heatmap displaying clustering of Spearman rank correlation of genes with TPM>1.
Replicates cluster together, after this some cluster by subcellular fraction, others by cell of
origin.
Clustering these expression datasets by Spearman rank correlation is shown in Fig 4.4.
Replicate datasets cluster together as would be expected, beyond that some samples are
clustering by fraction with the nuclear fractions of Gm12878, K562, Huvec and Hepg2
clustering together. While HEK and Nhek samples are clustering first by cell type, then by
cellular fraction. The HEK and Nhek cells were also those with the lowest fractions of intronic
fragments shown in Fig 4.1. Differences in the HEK and Nhek cells here could be due to
contamination of non-nuclear transcripts during cellular fractionation or genuine differences
between the distribution of transcripts in these cell types.
4.3.2 microRNA targeting - transcript diversity
40,600 microRNA targets were identified amongst all 9 CLASH datasets from Helwak et al.
Table 4.2 shows the count of how many hybrids were identified in multiple experiments, with
78% being observed in just a single experiment.
The count of microRNA targets annotated to different classes of transcript is shown in Fig 4.5,
with the highest categories being protein coding 3'UTRs followed by protein coding exons.
Many hybrids are also seen between microRNAs and repetitive elements including rRNAs,
LINEs, SINEs and tRNAs. Another large category of hybrids are those where the target
sequence is not present in the annotation dataset labelled ’unknown’.
After normalising for the total genomic sequence with each annotation, the number of hybrids
per megabase is shown in Fig 4.6. Here the category with the highest number of microRNA
targets are microRNAs themselves present in the dataset as microRNA duplexes. Of these 1032
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Table 4.2: Number of CLASH hybrids identified in 1 or more CLASH experiments of Helwak




















































































































































Figure 4.5: The count of microRNA hybrids annotated to different transcript classes. (X axis)
Transcript annotation. (Y axis) Count of microRNA hybrids with transcripts of that class. The
majority of transcripts targeted by microRNAs are protein coding genes along the full length
of transcripts and repetitive sequences.





















































































































































Figure 4.6: The count of microRNA hybrids annotated to different transcript classes normalised
to the genomic length of the annotation. (X axis) Transcript annotation. (Y axis) Count of
microRNA hybrids in transcripts of that class per megabase of the genome with that annotation.
Normalised in this way protein coding genes, lincRNAs, pseudogenes, rRNAs, tRNAs and
antisense transcripts display similar levels of microRNA binding, while microRNA duplexes
are enriched.
microRNA duplexes 240 are pairs of mature microRNAs from the same precursor hairpin, and
792 are duplexes of mature microRNAs from different precursor hairpins. As the total amount
of microRNA sequence in the genome is relatively small these microRNA-microRNA hybrids
appear more enriched in this plot after normalising for genomic sequence. This binding of
duplex microRNAs may represent an additional method that is used to control the level of free
microRNAs available to repress their gene targets.
The number of microRNA hybrids present at protein coding loci after this normalisation seems
more similar to other categories with rRNA, tRNA, lincRNA and antisense transcripts having
similar numbers of microRNA hybrids per megabase within two orders of magnitude 1,000 -
100,000 hybrids per megabase.
The remaining repetitive loci show low enrichment of microRNA hybrids when normalised for
genomic content, with LINEs, SINEs, low complexity and simple tandem repeats having fewer
than 10 hybrids per megabase of genomic sequence. This may be due to a large fraction of
the genome that these RNAs occupy, and their highly repetitive nature means they will have
reduced mapability so mapping reads would likely be discarded by the pipeline. However
the vast majority of these regions are likely to be non-transcribed, so this normalisation is
likely conservative considering level of transcripts produced by these regions. In CLIP like
experiments, alignments to these RNA species present at many copies in the genome are
often not considered, but these result suggest they may represent a substantial proportion of
microRNA targets.
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4.3.3 microRNA target specificity
Normalising for transcript abundance using RNAseq data is possible for long transcripts
captured by the RNA-seq protocol - protein coding genes, lincRNAs, and antisense transcripts.
Fig 4.7 shows scatter plots comparing each transcript for the number of CLASH reads
annotated to it and its expression level in TPM from whole-cell RNAseq, with quadratic lines of
best fit and their r2 values. Amongst the intronic categories a little relationship is seen between
transcript abundance and the number of CLASH reads with r2 values around 0. Antisense
transcripts also had little relationship in either the intronic or exonic segments. Amongst
the other categories; protein-coding, lincRNA, protein-coding 3'UTRs and 5'UTRs a positive
relationship is seen with r2 values ranging between 0.29 and 0.45. This positive relationship
can be seen particularly for transcripts with expression values >1 TPM. In HeLa cells it has
been estimated that a TPM of 1-10 corresponds to 1 copy per cell[235]. As intronic segments
will not be retained in the mature transcript their expression is likely not well captured by
this RNA-seq, however using expression data from the HEK nuclear fraction did not alter the
relationship seen here for intronic targets.
Similarly seen in Fig 4.8 the folding energies corresponding to microRNA:target base pairing
were stronger for exonic, 3'UTR or 5'UTR targets compared to intronic targets in both protein
coding and lincRNA transcripts.
Another metric for microRNA target reliability is the presence of non-hybrid reads at the target
locus as supporting evidence of a reliable interaction. Fig 4.9 shows the fraction of targets
that also have non-hybrid reads at the targets locus for each annotation category. The intronic
categories have the lowest fraction of supporting non-hybrid reads with ∼20-30% of targets,
while protein coding 3'UTRs, 5'UTRs and exons have the highest fraction of supporting non-
hybrid reds with >75% of targets. The remaining antisense exons, lincRNA exons, and other
categories have ∼50% of targets with supporting non-hybrid reads.
Of the 7431 Gencode v19[205] transcripts which contain microRNA targets identified as hybrid
CLASH reads only 251 transcripts contain multiple targets from the same microRNA. Using
Fisher’s exact tests to examine the enrichment of microRNA targets per transcript compared
with other microRNAs 6 microRNA-transcript combinations were robust to Bonferroni
correction for multiple testing listed in Table 4.3.
The top three enriched genes here: SERF2 (Small EDRK-Rich Factor 2) with two binding sites
for miR-1282, TARS2 (an aminoacyl-tRNA synthetase) with two binding sites for miR-6878,
and TRIP6 (Thyroid Hormone Receptor Interactor 6) with two binding sites for miR-6875, are
genes where the listed microRNA is also transcribed from the same locus, and the CLASH
binding sites are adjacent to the annotated microRNA loci. In these cases these target sites may
be due to un-annotated partner mature microRNAs, where the hybrid is actually a microRNA-
microRNA hybrid.
TP-73-AS1 an antisense non-coding RNA has three separate binding sites for miR-125a-5p,
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Figure 4.7: A comparison of CLASH and RNA-seq reads assigned to transcripts. (X-axis) log
of TPM value for each transcript calculated by Kallisto from whole cell RNAseq. (Y-axis)
log of CLASH reads annotated to each transcript. A separate graph is drawn for each class of
transcripts, the ’other’ class contains other classes of transcripts listed in the Gencode v19[205]
annotation: processed transcripts, sense intronic, sense overlapping. Lines of best fit are shown
calculated with linear regression using second order polynomials, 95% confidence intervals
for this line are shown in grey, adjusted r2 values for these models are shown. Amongst non-
intronic transcript segments CLASH binding is correlated with gene expression.




























Figure 4.8: Folding energy distribution of microRNA:target chimeras in (a) segments of











SERF2 miR-1282 2 0 1 15246 2.58E-08
TARS2 miR-6878-3p 2 2 0 15245 5.16E-08
TRIP6 miR-6875-3p 2 2 0 15245 5.16E-08
TP73-AS1 miR-125a-5p 3 0 86 15160 1.92E-07
MAP3K1 let-7g-5p 2 1 11 15235 2.01E-06
CDR1 miR-7-5p 2 1 21 15225 6.52E-06
Table 4.3: Genes enriched for specific microRNA targets. Numbers represent counts of targets
for the microRNA listed or all other microRNAs, within the gene listed or within all other
genes. Making the contingency table for a Fisher’s exact test pvalue shown.



























































































Figure 4.9: The fraction of microRNA targets with supporting non-hybrid reads. (X axis)
Transcript annotation category. (Y axis) Fraction of microRNA targets with supporting non-
hybrid reads. As hybrid reads are a subset of CLASH reads, additional supporting evidence
from non-hybrid reads indicates a more reliable interaction.
with no other microRNA targets. These hybrids have been identified from 1, 1 and 2 sequencing
reads with no non-hybrid reads overlapping their target sites. This would be a potential genuine
target or competitive RNA for miR-125a.
MAP3K1 has two targets for let-7g-5p in its 3'UTR, the only other microRNA targeting this
gene is let-7a with a target site overlapping one of the let-7g sites. This may represent genuine
gene target for the let-7 family.
CDR1 (Cerebellar Degeneration Related Protein) with two binding sites for miR-7 is
an example of a circular competitive RNA previously identified to compete for miR-7
binding[160], discussed more in section 4.3.7.
Using the number of CLASH reads for a target as a proxy of the strength or reliability of
binding and examining each microRNA individually will allow the identification of the classes
of transcript they bind and allow the identification of those transcripts which are highly bound
by Argonaute compared to their expression level. Fig 4.10 shows scatter plots comparing
the number of CLASH reads to transcript expression level for the 12 microRNAs with the
highest number of targets. Lowly expressed transcript on these graphs with a high number
of CLASH reads are likely transcripts such as short RNAs which are poorly captured by the
RNA-seq procedure used. Mitochondrial RNAs shown in green while amongst the most highly
expressed transcripts detected are often bound less than would be expected for their expression
level, appearing below the lines of best fit.
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The linear models shown as the lines of best fit for these 12 microRNAs have adjusted
R squared values of between 0.22 and 0.51 (median 0.31), demonstrating that transcript
expression level explains a large fraction of the variance in this data.
10 Genes with the largest difference between the linear model predicted value and actual for
CLASH reads are labelled, representing candidates for genuine targeting for repression or a
competitive endogenous RNA (ceRNA) effect. Several transcripts are commonly found in
these lists of genes with more CLASH reads than predicted, they include highly expressed
such as ribosomal proteins (RPL30, RPL31) and tubulin (TUBA1B) with TPM>1000 in
the top 0.7% of genes by expression. Other genes bound more strongly than expected by
expression value by multiple microRNAs are; DHFR, HSPA1A, GLUL, GRAMD1A, VDAC1,
REEP4, EIF3CL, and SMARCC1. With TPM ranging between 40 and 200 in the top 20%
of genes by expression. These genes may represent those which are poorly captured in the
RNA-sequencing experiment, or may be common targets able to bind easily to a variety of
microRNAs.
Other genes bound more than predicted for a single microRNA using the linear model based
on their expression are listed in Table 4.4. These may be candidates for gene-specific targets
for repression or competitive endogenous RNAs (ceRNAs) with single, but highly bound by
Argonaute target sites.
4.3.4 Modelling microRNA targeting
As discussed above linear models using only transcript expression as a predictor can explain
∼28% of the variation in CLASH reads per transcript. Here I use additional features of
microRNA targeting to model the variation in CLASH reads for each transcript. Using
a random forest algorithm I examine the parameters which best predict CLASH reads per
transcript. Features included in the model are: transcript expression level (whole cell, cytosolic,
or nuclear), GC content of target site, distance from stop codon (for protein coding transcripts),
folding energy (a measure of how well the microRNA and its target base-pair), seed type
(whether base-pairing is present for 6, 7 or 8 bases of the seed region) and the part of the
transcript a microRNA is targeting (intron/exon/5'UTR/3'UTR).
Creating separate random forest models for each of 23 microRNAs which have more than
200 CLASH hybrid loci with these parameters, models have r2 values between 0.19 and 0.61
(median 0.39) showing a wide variation in how well these models explain the variation in
assigned CLASH reads. This suggests that the features predictive of targeting may differ
between microRNAs, with some not being captured by the models in use here.
Fig 4.11 shows a boxplot with the distribution in variable importance measures assigned to the
each parameter for each of the 23 microRNAs analysed. As expected expression values for
either whole cell or a cellular fraction are the most important variables, with whole cell more
often the most predictive.
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Figure 4.10: Comparison of transcript expression and number of CLASH reads. (X-axis) log
of TPM value for each transcript calculated by Kallisto from whole cell RNAseq. (Y-axis) log
of CLASH reads annotated to each transcript. A separate graph is drawn for each microRNA.
Points are coloured by the transcript class they represent: black=protein-coding, red=lincRNA,
green=mitochondrial RNA. Lines of best fit are shown calculated with linear regression using
second order polynomials, 95% confidence intervals for this line are shown in grey. The top
10 transcripts ordered by difference between value predicted by the linear model and actual
number of CLASH reads for each microRNA with >10 TPM are labelled.
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microRNA gene expression (TPM) actual reads predicted reads
miR-484 UQCRQ 353.6 278 20.7
miR-484 PKM 678.6 277 29.8
miR-484 C6orf48 80.7 242 9.8
miR-484 SYNGR2 78.1 190 9.6
miR-484 SRSF9 258.5 152 17.5
miR-484 H2AFX 99.9 123 10.8
miR-484 COX5A 350.5 129 20.6
miR-92a-3p PARK7 347.0 458 20.5
miR-92a-3p ZNF703 59.1 320 8.5
miR-92a-3p PPP1CC 168.4 215 14.0
miR-92a-3p STUB1 234.0 173 16.6
miR-615-3p TMED2 125.4 222 12.1
miR-186-5p NDUFA7 88.9 315 10.2
miR-186-5p EEF1A1 4907.3 334 104.3
miR-186-5p CBX3 278.8 222 18.2
miR-186-5p CNBP 324.3 201 19.7
miR-186-5p PDCD5 266.0 142 17.7
let-7b-5p PSMB4 323.4 612 19.7
let-7b-5p LSM3 31.4 219 6.4
let-7b-5p EEF1G 1518.7 226 48.4
miR-320a EIF3L 307.4 567 19.2
miR-320a SNRPB 557.2 161 26.6
miR-30c-5p UBE2D2 89.1 244 10.2
let-7a-5p NDUFAF3 116.3 173 11.6
let-7e-5p AGRN 22.7 296 5.6
let-7e-5p SERBP1 386.0 222 21.7
let-7e-5p GNG5 113.0 128 11.5
Table 4.4: Genes with >100 more CLASH reads than predicted using the linear models
displayed in figure 4.10 based on their expression in transcripts per million (TPM).







































Figure 4.11: Variable importance in predicting CLASH binding. (X-axis) random forest
model parameter. (Y-axis) variable importance measure calculated using AUC based variable
permutation[234]
Distance to stop codon is significantly predictive for 3'UTR and exon targets with a smaller
distance being predictive of higher numbers of reads, suggesting that targets at final exons and
at the 5’ end of 3'UTRs were stronger hybrids with more CLASH reads.
Transcript part (exon, intron, 5'UTR, 3'UTR) is predictive with intron targets having a negative
weight, 3'UTR and exon targets having a positive weight. 5'UTR targets are not significantly
predictive. GC content of target site is also shown as a useful predictor here, with higher GC
negatively correlated to CLASH reads.
Folding energy and seed type (8mer, 7mer, 6mer) have been previously seen to be a useful
factor for predicting the activity of microRNAs[96], and folding energy has been used
previously in this chapter as a measure of specificity having different distributions between
exonic and intronic targets (Fig 4.8). However in this analysis both are the least predictive
parameters for the number of CLASH reads present at a targeted locus. This may be because
while a well base-paired microRNA with binding in the seed region are required for target
repression they are not necessary for target binding, with perhaps a larger pool of more poorly
bound transient targets.
4.3.5 microRNAs targeting transcription start sites
A number of studies have suggested a role for microRNAs in transcriptional gene
regulation[137, 231, 139, 132, 144, 147, 141] (section 1.5.3). Here I test this hypothesis by
examining for enrichment of specific microRNAs with targets around transcription start sites.
11,385 robust transcription start site loci were obtained in HEK293 cells from cap analysis of
gene expression sequencing (CAGE-seq)[236] as part of the FANTOM5 project[207].
Intersecting regions upstream of these TSSs identified 936, 704, and 584 microRNA targets
within 200bp, 100bp and 50bp upstream of TSSs respectively.
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microRNA tss miRNA tss others non-tss miRNA non-tss others pvalue
let-7c-5p 10 339 116 22809 2.1E-05
Table 4.5: MicroRNAs enriched for CLASH targets within 50bp upstream of TSSs. Numbers
represent counts of targets for the microRNA listed or all other microRNAs, within 50bp
upstream of the TSSs or all other targets. Making the contingency table for a Fisher’s exact
test, pvalue shown.
microRNA tss miRNA tss others non-tss miRNA non-tss others pvalue
miR-1307-3p 9 362 51 22256 5.4E-07
miR-935 9 362 75 22232 9.5E-06
Table 4.6: MicroRNAs enriched for CLASH targets within 50bp downstream of TSSs.
Numbers represent counts of targets for the microRNA listed or all other microRNAs, within
50bp downstream of the TSSs or all other targets. Making the contingency table for a Fisher’s
exact test, pvalue shown.
Testing microRNAs with more than 10 hybrids excluding those targeting repeat sequences and
microRNA loci using Fisher’s exact tests for enrichment of targets within 50bp,100bp or 200bp
upstream of FANTOM5 transcription start sites identified 1 significant microRNA robust to
Bonferroni multiple testing correction shown in Table 4.5. Let-7c was significantly enriched
for binding upstream of TSSs because of 12 binding sites mapping to RNAs encoded on the
mitochondrial chromosome, listed as upstream regions due to the gene density of the region.
Other than this there was no enrichment for particular microRNAs binding at transcription start
sites.
Intersecting regions downstream of these TSSs identified 1838, 1303, and 939 microRNA
targets within 200bp, 100bp and 50bp downstream of TSSs respectively.
Testing was performed microRNAs with more than 10 hybrids excluding those targeting repeat
sequences and microRNA loci using Fisher’s exact tests for enrichment of targets within
50bp,100bp or 200bp downstream of FANTOM5 transcription start sites. This identified two
microRNAs listed in Table 4.6: miR-1307-3p and miR-935 each with 9 targets within 50bp
downstream of TSSs. These targets seemed to be biased towards highly expressed genes with
the median TPM for miR-1307-5p TSS targets being 369 TPM in the top 1% of transcripts
by expression. For miR-935 the median TPM for TSS targets was 33 TPM in the top 10% of
transcripts by expression.
4.3.6 microRNAs targeting splice sites
A number of studies have suggested a role for Argonaute in altering splicing[154, 153, 151,
150] (section 1.5.4), here I examine the distribution of microRNA targets around splice sites
and test for enrichment of specific microRNAs with targets around splice sites.
Intersecting the 3p and 5p ends of introns from Gencode v19[205] with CLASH microRNA










miR-615-3p 345 6109 518 15706 8.3E-14
miR-92a-3p 377 6077 621 15603 5.0E-11
miR-149-5p 136 6318 203 16021 2.2E-06
miR-92b-3p 79 6375 104 16120 1.4E-05
miR-222-3p 117 6337 180 16044 2.9E-05
miR-103a-3p 127 6327 211 16013 1.6E-04
miR-484 364 6090 732 15492 2.4E-04
Table 4.7: MicroRNAs enriched for CLASH targets within 50bp of splice sites. Numbers
represent counts of targets for the microRNA listed or all other microRNAs, within 50bp of
splice sites or all other targets. Making the contingency table for a Fisher’s exact test, pvalue
shown.
targets identified 7092, 9256, and 11375 targets allowing windows of 50p, 100p, and 200bp
respectively, representing 30%, 40%, and 49% of protein-coding and lincRNA targets due to
the density of targets in exonic sequence.
Testing microRNAs with more than 10 hybrids excluding those targeting repeat sequences
and microRNA loci using Fisher’s exact tests for enrichment of targets within 50bp of splice
junctions identified 7 microRNAs listed in Table 4.7.
100bp flanking either side of Gencode v19[205] introns were intersected with microRNA target
sites to examine the distribution of targets around splice sites. Fig 4.12a shows that targets were
more highly enriched within the exons. However examining individual microRNAs showed a
peak around the end of the intron at splice acceptor sites for microRNA miR-320a seen in
Fig 4.12b. Although miR-320a was not enriched at splice sites compared to other targets in the
Fisher’s exact tests above with 210 target sites within 10bp of splice junctions, and 330 other
targets giving an odds ratio of 1.01 and pvalue 0.15 compared with all other microRNAs.
4.3.7 microRNAs targeting circular RNA ‘sponges’
Circular RNAs have been observed in human cells and are suggested to act as ceRNAs or
’microRNA sponges’ acting to sequester microRNAs[159, 160, 161] (section 1.6). Intersecting
CLASH microRNA hybrids with a dataset of 1953 circular RNAs identified in HEK293 cells
by Memczak et al[160] I find 602 circRNA-microRNA pairs involving 322 circRNAs and 162
microRNAs.
Using Fisher’s exact tests to identify microRNAs which were enriched for targeting predicted
circular RNAs, compared with all other microRNA targets, no microRNAs were robust to
Bonferroni correction. Those passing nominal significance are shown in Table 4.8, the most
significant of these miR-7 with three targets in predicted circular RNAs was the microRNA
identified in Memczak et al.[160] as being sequestered by a circular RNA named CDR1as.
Two of the three binding sites listed for this microRNA in Table 4.8 were within CDR1as.























Figure 4.12: Distributions of microRNA targets around spice junctions. (Left panels) 200bp
around splice donor sites. (Right panels) 200bp around splice acceptor sites. (A) All
microRNA target sites. (B) miR-320a target sites.
microRNA circ miRNA circ others non-circ miRNA non-circ others pvalue
miR-7-5p 3 360 34 22281 0.021
miR-92b-3p 7 356 176 22139 0.028
let-7g-5p 2 361 18 22297 0.040
miR-125a-3p 2 361 18 22297 0.040
miR-6807-3p 3 360 47 22268 0.046
Table 4.8: MicroRNAs enriched for CLASH targets within circular RNAs. Numbers represent
counts of targets for the microRNA listed or all other microRNAs, within predicted circular
RNAs or all other targets. Making the contingency table for a Fisher’s exact test, pvalue shown.
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4.4 Chapter summary
Applying the genome-wide hybrid mapping pipeline discussed in the previous chapter to nine
AGO1 CLASH datasets from Helwak et al. identified∼40,000 microRNA binding sites across
a variety of transcript classes. Most abundant amongst these were targets within protein coding
genes, particularly 3'UTRs as expected for microRNA mediated gene repression, and also
within internal exons, 5'UTRs and introns. Another abundant class of targets were repetitive
elements, particularly rRNAs, tRNAs, LINEs, and SINEs. Also present were targets within
lincRNAs, pseudogenes, and antisense RNAs. These microRNA targets across the length of
protein-coding transcripts and in a variety of non-protein-coding transcripts may represent
chance binding events due to partial complementarity or may be functional for an effect in
controlling free microRNA levels or other affects mediated by Argonaute interactions with
other effector proteins.
A number of studies have suggested a role for microRNAs in affecting transcription where
being targeted near TSSs Argonaute can interact with chromatin remodellers to affect
accessibility. Testing for enrichment of microRNA targeting upstream of TSSs revealed only
an artefact due to a high level of Let-7c binding to mitochondrial genes which have many
close TSSs in the CAGE dataset. Two microRNAs miR-1307-5p and miR-935 were enriched
for targeting downstream of proximal TSSs, each targeting nine genes within 50bp of a TSS,
biased towards highly expressed genes.
Some studies have also suggested a role for microRNAs in affecting splicing via Argonaute
interactions with splicing factors. Testing microRNAs for enrichment of targets around splicing
acceptor or donor sites seven microRNAs were enriched for targets within 50bp, although
30% of protein coding or lincRNA targets fell within these windows and each of these
seven microRNAs had more non-splice-site targets than splice-site targets suggesting these
interactions were not specific. Similarly the peak of miR-320a binding around splicing acceptor
sites is likely due to complementarity to the consensus sequence around this site, despite this
miR-320a was not enriched for binding at these regions compared to other microRNAs.
Circular RNAs have been hypothesised as a source of ceRNAs with one striking example for
miR-7. No microRNAs were significantly associated with predicted circular RNAs, although
the microRNA with the most significant pvalue was for miR-7 with its previously identified
ceRNA CDR1as. This result would support the hypothesis that the majority of circular RNAs
were low abundance splice variants.
Testing amongst all Gencode v19[205] transcripts for those enriched with multiple binding
sites identified: The CDR1 transcript previously known with miR-7 binding sites. MAP3K1
with binding sites for let-7a/let-7g and TP73 antisense transcript with 3 binding sites for miR-
125a-5p candidate targets or ceRNAs. And three transcripts SERF1, TARS2 and TRIP6 with
multiple binding sites for microRNAs where the pre-microRNAs are contained within these
genes, probably representing their mis-annotated or un-annotated mature microRNAs.
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Examining correlations between transcript abundance in RNA-seq data and the level of CLASH
binding to transcripts positive correlations could be seen above a transcript abundance threshold
for exon lincRNA targets and exon, 3'UTR, and 5'UTR protein-coding gene targets. These
correlations were not seen for intronic targets and were less strong in antisense RNAs. It would
be expected that transcript expression level would strongly correlate with microRNA targeting,
where these correlations are not present for intronic targeting it may be due to transcripts which
are not well captured in this RNA-seq dataset. Additionally candidates for targets for repression
or ceRNAs may be seen as deviations from this expected level of targeting given transcript
abundance, some of which appear to be common to several of the microRNAs examined while
others are microRNA specific.
Weaker or more transient targeting in introns was also suggested by the calculated RNA folding
energy as a measure of how well microRNAs base-paired with their targets which was weaker
for targets at intronic sites, and similarly strong in protein-coding exons, 3'UTRs, 5'UTRs and
lincRNA exons.
Modelling the correlation between expression level and CLASH targeting on a per-microRNA
basis revealed differences in the strength of this correlation. Examining those transcripts which
are bound by specific microRNAs more often than would be expected for their expression level
demonstrated candidate targets for repression and potential competitive RNAs.
Modelling other parameters which may contribute to microRNA targeting revealed that while
target expression was most predictive, also predictive were; smaller distance to stop codon,
exon or 3’UTR targets and target site GC%. Folding energy and binding in the seed region,
while previously seen as important for transcript repression were not predictive for the level
of CLASH reads at a target site, perhaps due to a larger pool of more weakly bound but not
repressed targets being analysed here.
As well as deviations from expected levels of CLASH binding according to transcript
abundance, a clustering approach may identify transcripts or regions of transcripts which were
more highly bound by Argonaute than expected by chance. This will be examined in the next
chapter.
Chapter 5
Clustering of microRNA targets
5.1 Introduction
microRNAs as part of the RISC complex repress their protein-coding targets through
complementary base-pairing with sites in their 3'UTR (section 1.5). This activity is dependent
on the microRNA:target ratio, where additional microRNA targets above a certain threshold
will act to reduce the repression on microRNA targets. It has been hypothesised that in order
to affect microRNA repression a substantial number of additional target sites will be necessary
requiring highly expressed transcripts with small numbers of binding sites or expression of
transcripts with a large number of microRNA target sites (section 1.6).
Chapter 4 examined transcripts for the enrichment of microRNA hybrids involving the same
microRNA, identifying three transcripts TP73-AS1 and miR-125a, maP3K1 and let-7, and
CDR1 and miR-7.
This chapter examines the spatial clustering of all microRNA hybrids within the genome to
identify exons or regions of genes which are densely bound by Argonaute, and may represent
candidate competitive endogenous RNAs (ceRNAs).
5.2 Methods
5.2.1 Data
Datasets analysed here are the CLASH hybrid and CLASH non-hybrid genomic locations from
chapter 4. These datasets were separately merged using the BedTools merge function such that
several hybrids targeting the same site would be counted as a single site for clustering.
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5.2.2 Genome-wide clustering
A clustering approach was implemented in R to identify spatial clusters of binding sites using a
dynamic programming approach. This algorithm generated scores along the genome such that:
• A new binding sites added a score of m
• Within a binding site scores remained the same
• Not within a binding site scores decay to 0 by n per base.
Backtracking is then performed to identify clusters in order of their maximum score above a
threshold:
• Starting with the highest score, the region before that point until the score reaches 0 is
recorded as a cluster
• That region is masked
• Scores for the region beyond that maximum score point are recalculated, and the next
highest score is recorded
This approach allows clusters to grow dynamically rather than using fixed size windows.
Selected parameters for the algorithm were a score of 30 for each new binding site with a
decay of 0.2 per base, clusters were identified with a score above 31. Sample results of the
clustering algorithm are shown in Fig 5.1.
5.3 Results
5.4 Clustering microRNA binding sites
Applying the clustering algorithm to CLASH microRNA targets identified 349 cluster of
multiple target sites. Counts of these clusters with the Gencode v19[205] transcripts they
overlap with are shown in Fig 5.2, often clusters would overlap multiple regions of protein-
coding genes due to alternatively spliced transcripts or alternative 3'UTR sites.
Only six clusters of microRNA targets did not overlap any Gencode v19[205] transcript
(table 5.1). Two of these (IDs 27 and 249) corresponded to small nucleolar RNAs not present in
Gencode v19. The remaining four regions had overlapping mRNA sequences from GenBank
seen on the UCSC genome browser, but no annotated transcripts.
Eleven clusters of microRNA targets are present within predicted circular RNAs by Memczak
et al.[160]. Shown in table 5.2 these results are biased towards highly expressed genes
providing a greater opportunity for base-pairing in a small genomic region. Clusters with the
MYH9, KPNB1, DDX5, HNRNPA2B1 and CANX genes are present at predicted circularised










Figure 5.1: Example scores generated by the clustering method. Black boxes below 0 represent
sites of Argonaute binding, the score calculated in the first pass is shown on the Y axis, new
binding sites increase the score while there is a drop-off penalty. The red line shows the
threshold for clusters with more than one binding site. Clusters identified by the algorithm



































































































Figure 5.2: The count of microRNA hybrid clusters from hybrid CLASH reads annotated
to different transcript classes. (X axis) Transcript annotation. (Y axis) Count of microRNA
clusters annotated to that class.
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ID chr start end length score
27 chr19 50595748 50595865 117 58
41 chr13 110076545 110076633 88 57
57 chrM 240 411 171 57
86 chr2 71127445 71127491 46 55
222 chr7 10492980 10493044 64 46
249 chr19 48421688 48421804 116 42
Table 5.1: Clusters of microRNA targets sites with no gencode v19 annotation corresponding
to unannotated transcripts
gene region chr start end score tpm
MYH9 exon chr22 36684297 36684391 47 50.6
KPNB1 exon chr17 45747066 45747127 55 334.5
DDX5 exon chr17 62500843 62500905 57 359.7
BCL7A intron chr12 122473442 122473506 32 19.4
HNRNPA2B1 exon chr7 26235465 26235531 52 1258.8
CANX exon chr5 179132682 179132731 58 247.4
HIST1H1E exon chr6 26156943 26156997 56 0.3
HIST1H2AG exon chr6 27101195 27101287 41 0.7
HIST1H2BK exon chr6 27114559 27114616 56 35.9
HIST1H2BK exon chr6 27114152 27114273 46 35.9
HIST1H4E exon chr6 26205084 26205136 53 0.1
Table 5.2: Clusters of microRNA targets sites within predicted circular RNAs. Score = cluster
score, TPM=Transcripts per million (transcript abundance)
exons, or segments of exons. The cluster within an intron of BCL7A is part of a predicted
13kb circular RNA formed through a retained intron. Five clusters of microRNA binding sites
within two histone gene clusters on chromosome 6 are also seen, where circular RNAs are
predicted as forming between histone genes. These circular RNAs may be mis-annotations due
to similarity of histone genes or genuine trans-splicing events. Transcripts from these genes
while not well captured in the RNA-seq experiment will be highly expressed.
Two miR-7 targets within CDR1-as, the previously seen ceRNA, are hybrids located ∼1kb
apart in this dataset so are not rediscovered as a cluster in this analysis.
5.4.1 Clustering Argonaute binding sites
As captured CLASH microRNA hybrids are likely a subset of sites, examining all Argonaute
binding sites through clustering of the non-hybrid CLASH reads may provide a distribution
less biased to highly expressed transcripts.
Performing the same clustering approach for these reads finds clusters amongst the transcript
types shown in Fig 5.3
Intersecting these hybrids with predicted circular RNAs from Memczak et al.[160] identifies

























































































































































Figure 5.3: The count of Argonaute hybrid clusters identified from all CLASH reads annotated
to different transcript classes. (X axis) Transcript annotation. (Y axis) Count of microRNA
clusters annotated to that transcript class.
gene region chr start end score tpm
AMOTL1 UTR3 chr11 94604690 94609833 422 12.4
FBXO34 UTR3 chr14 55817619 55820331 338 10.8
MED1 UTR3 chr17 37560733 37566977 336 42.7
MRPS25 UTR3 chr3 15083925 15090778 325 72.7
WDR6 UTR3 chr3 49048976 49051728 320 131.6
MALAT1 exon chr11 65266354 65273646 317 4.6
RBM12 UTR3 chr20 34237731 34243284 306 54.2
UCK2 exon chr1 165877971 165880925 286
LMTK2 exon chr7 97820924 97823790 281 5.4
ARHGAP35 exon chr19 47422854 47425055 242 8.5
ATXN7L3B UTR3 chr12 74931494 74935221 240 48.9
FAT1 exon chr4 187627716 187630946 224 21.2
LRRC58 UTR3 chr3 120046869 120050077 219 13.6
TMEM194A UTR3 chr12 57449430 57453844 216 19.8
ZNF544 UTR3 chr19 58772908 58774575 206 34.6
MAP4 UTR3 chr3 47892828 47894621 195 61.0
VKORC1L1 UTR3 chr7 65419060 65422179 191 15.7
SPIN1 UTR3 chr9 91090016 91092406 185 21.1
LMNB2 UTR3 chr19 2428163 2430954 180 65.9
DYNLL2 UTR3 chr17 56166500 56169397 179 20.5
Table 5.3: Clusters of Argonaute binding sites within predicted circular RNAs. Score = cluster
score, TPM=Transcripts per million (transcript abundance)
459 clusters amongst 364 predicted circular RNAs. The majority of these are annotated as
either protein-coding exons, or protein-coding 3'UTRs. The top 20 of these clusters by score
are listed in table5.3, where a cluster within the lincRNA MALAT1 is also seen.
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5.5 Chapter summary
In chapter 4 the enrichment for the binding of specific microRNAs to transcripts was examined.
In this chapter multiple microRNA target sites or Argonaute binding sites within relatively
small regions of the genome were analysed regardless of identified targeting small RNAs.
These clusters of binding sites were typically present at protein-coding UTRs and protein
coding exons.
3'UTRs are an expected target of genuine transcript repression, whereas circularised protein-
coding exons have been hypothesised as a source of competitive endogenous RNAs. Few
clusters of binding sites were present outside of Gencode v19[205].
It was also observed in chapter 4 that gene expression was a major factor in observing
microRNA binding, and clusters of microRNA targets sites seen here are biased towards highly
expressed transcripts.
Examining clusters of Argonaute binding from non-hybrid reads, a more dense dataset,
identifies spatial clusters seen here often within single exons or 3'UTRs which are less biased
towards highly expressed transcripts, some of which are present within circular RNAs and may
represent good candidates for competitive endogenous RNAs.
As few clusters of binding sites in unexpected locations were identified, and few enrichments
for the binding of specific microRNAs to transcripts was seen these results have not been
followed up in detail.
The remaining chapters of this thesis explore the second of my project aims: to examine the






The key pathways in the production of microRNAs in humans have been uncovered with
further details of their mechanisms continuing to be elucidated (section 1.3.1). In the canonical
microRNA biogenesis pathway microRNAs are transcribed as pri-microRNAs containing one
or more regions which form hairpin loops in their secondary structure. These hairpin loops
are recognised and cut in the nucleus to form pre-microRNAs by the microprocessor complex
comprised of the double stranded RNA binding protein DGCR8 and the RNase III enzyme
dicer. pre-microRNAs are then exported to the cytoplasm where a second processing event is
carried out by another RNase III enzyme Dicer producing mature microRNAs which may then
be loaded into Argonaute proteins to form the RISC complex which can regulate the expression
of other genes.
The effect of genetic variation between individuals in affecting microRNA biogenesis has been
examined in a number of studies correlating gene expression measures from expression arrays
or small RNA sequencing with genotype data from SNP genotyping arrays or whole-genome
sequencing to identify eQTLs (section 1.7.2).
As the power of these studies has increased through sample size and density of genotyping
they have identified increasing numbers of microRNA eQTLs. Using SNP genotyping arrays
finding cis-eQTLs for 6[183], 12[182], and 14[184] microRNAs. And using samples whole-
genome sequenced through the 1000 Genomes Project has identified cis-eQTLs for 31[185]
and 60[186] microRNAs. The most recent and largest of these studies was performed by
the GEUVADIS consortium[186] utilising small RNA sequencing in 452 lymphoblastoid cell
lines (LCLs) with whole-genome sequencing to an average depth of 5x and exome sequencing
to an average depth of 80x from the 1000 Genomes Project[204]. They identified 3868
60
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SNPs which were cis-eQTLs to 60 microRNAs (within 500 kb). However no attempt was
made to consider potential functional variants at these quantitative trait loci or identify likely
mechanisms explaining the expression-level molecular-phenotypes. Indeed the mechanisms
by which eQTL variants affect microRNA expression has only been examined in a handful of
cases with disease relevance(section 1.7.4).
In this chapter I examine the distribution of SNP variants at microRNA loci and the evidence
for their selective constraint. I examine microRNA cis-eQTL SNPs from the GEUVADIS
consortium[186] and identify additional rare cis-eQTL variants, assessing their potential to
affect processing. These cis-eQTLs SNPs are then be compared with those that do not affect
microRNA expression to examine purifying selection and the features of microRNA hairpins
which when disrupted are likely to affect expression leading to a phenotypic consequence.
Identified cis-eQTLs are then prioritised for further analysis such as that applied to the variant
in the terminal loop of miR-30c[199] (section 1.7.4) to confirm their effect and examine the
mechanism through which they act. I then apply this knowledge about how variants affect




The GEUVADIS consortium[186] identified cis-eQTLs from SNPs within 500kb of their
curated list of microRNA loci, this list of microRNA loci was an extension of miRBase
v18[11] where if only one mature microRNA was annotated from a microRNA hairpin
the partner mature microRNA was annotated using RNA structure prediction. Only those
mature microRNAs detected as expressed in >50% of samples were used in eQTL detection,
expression values corresponding to read count normalised to the median number of well-
mapped reads to account for variation in sequencing depth. Where variants overlapped mature
microRNAs sequences the non-reference alleles were generated to account for allelic mapping
bias. cis-eQTLs were calculated using the matrixEQTL R package v2.1.1[224].
I have filtered these significant microRNA cis-eQTLs published by the GEUVADIS consortium
for variants within 20bp of the miRBase microRNA hairpin they are an eQTL for. This
identified 20 SNPs which were cis-eQTL to the microRNA hairpin they were contained within
or were adjacent to.
These candidates were then examined as to whether they were previously known or belong to
blocks of linkage disequilibrium associated with expression, whether they were the strongest
cis-eQTL signal for the microRNA, and whether they disrupted any known structural or
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sequence motifs.
Rare SNPs
All bi-allelic SNPs within miRBase v18 microRNA hairpins +/- 20nt were extracted from
GEUVADIS vcf files (EBI ArrayExpress accession: E-GEUV-1) using bcftools[219] v1.2-5
for testing with the R package MatrixeQTL[224] v2.1.1, using an additive linear regression
model with a t-statistic test corrected for multiple testing using the Benjamini-Hochberg
procedure.
As the power to call significant rare variant eQTLs is reduced relative to common SNPs due to
the smaller numbers of rare genotype samples, results were selected based on a less stringent p-
value threshold of corrected p-value<0.1 as well a threshold on the magnitude of the expression
change with the heterozygous genotype having a median expression greater than 0.5 times the
standard deviation of the common homozygote away from the common homozygote median
expression.
Multivariate linear regression and analysis of variance using the R functions lm and anova
from the stats package with default parameters were used to examine the independence of
eQTL signals where multiple SNPs at a loci displayed significance.
6.2.2 Annotation
SNPs were annotated with their microRNA locus finding overlaps for their genomic
coordinates with bedtools intersect. Based on miRBase annotation of microRNA
processing cleavage sites and stem-loop base pairing structure, each microRNA hairpin was
split into consecutive segments: 3p and 5p flank, 3p and 5p stem, 3p and 5p mature microRNA,
and hairpin loop. SNPs were then annotated with their microRNA region accounting for
microRNA strand orientation.
6.2.3 Derived allele frequency tests
The frequency distribution of derived alleles can be used to compare selection at different
genomic regions. Derived allele frequency tests were performed using SNPs found in
the uniform whole-genome coverage (median 20x) of 2636 individuals in the Icelandic
population[210]. Variants were resolved into ancestral and derived alleles through reference
to the Ensembl human ancestor reconstructed sequence based on the 12-way mammalian
EPO alignments. Variants with unresolved ancestral states and non-single-nucleotide
polymorphisms were discarded. The genome-wide allele frequency distribution was used as
a proxy for neutral evolution. Where purifying selection acts to remove deleterious alleles an
excess of rare alleles will be seen relative to common alleles. Where diversifying selection
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acts to increase the allele frequency of new beneficial alleles an excess of common alleles
will be seen relative to rare alleles. Statistical tests were performed with a Fisher’s exact test
using the R function fisher.text from the stats package giving the odds ratios and 95%
confidence intervals. Common alleles are defined as those with a MAF>5%, rare alleles those
with a MAF<1.5%, these values were chosen to maximise the odds ratio while minimising the
confidence interval for a comparison between second codon positions and four-fold degenerate
sites in amino acid sequences[237].
6.2.4 Odds ratio tests
The odds ratio for SNPs in each microRNA region being a cis-eQTL was calculated with
a Fisher’s exact test using the R function fisher.test from the stats package compared
to all SNPs flanking hairpins up to 1kb where ∼3% (196/6431) were cis-eQTLs (corrected
pvalue<0.05).
6.3 Results
6.3.1 The distribution of common microRNA SNPs
Examining the distribution of SNPs across microRNA loci using all variants found in
dbSNP[208] v139 shown in Fig 6.1 we can see many variants are present, fairly evenly
distributed across the whole of microRNA loci. A reduced number of common (>5% minor
allele frequency) variants may be present around a number of sites: 1bp upstream from the 3p
microRNA, and around the base of hairpins at positions -12 to -14 in the 5p-flank and 9 to 11
in the 3p-flank. However this analysis has very little power to detect these changes, and does
not account for nucleotide composition.
6.3.2 Selective constraint at microRNA loci
To examine the evidence for selection acting at microRNA loci derived allele frequency tests
were performed, comparing the frequency of derived alleles across the whole genome as a
proxy for neutral evolution to the frequency of derived alleles at whole microRNA loci, and
within each annotated microRNA region. Fig 6.2 shows evidence for selective constraint at
microRNA loci taken as a whole, although less than at protein coding codons, while in the
segment analysis the lower numbers of SNPs give large error bars overlapping the background
distribution in some cases.
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(a) Position around 5p end of miRNA-5p





































(b) Position around 3p end of miRNA-5p






































(c) Position around 5p end of miRNA-3p






































(d) Position around 3p end of miRNA-3p
Figure 6.1: The distribution of dbSNP SNPs at microRNA loci, centred around mature
microRNA boundaries shown in the top figure. Grey lower panels: count of SNPs at sites,
Blue upper panels: count normalised to the number of sites present.
















Derived allele frequency odds ratio
Figure 6.2: Odds ratios of derived allele frequencies for rare(<1.5%) and common(>5%)
derived alleles comparing the genome wide distribution to the region labelled, either
whole microRNA loci or their annotated segments, protein coding codons are included for
comparison. Odds ratios of 1 indicate equality with the genome-wide distribution, higher
values indicate selective constraint, and values less than 1 are indicative of net positive
selection. The number of SNPs in each category are shown in parenthesis next to the axis
labels.
6.3.3 Common microRNA SNPs are cis-eQTLs
Intersecting those common SNPs identified as microRNA eQTLs by the GEUVADIS
consortium with miRBase v18[11] precursors +/- 20bp identified 20 SNPs which were a cis-
eQTL to a mature microRNA from the hairpin that they were within or adjacent to (Table 6.1).
Fig 6.3 shows regional association plots displaying all of the cis-eQTLs up to 500kb away for
the selected microRNAs and boxplots displaying the microRNA expression for each genotype
of the selected SNP. In some cases the selected SNP present at the microRNA hairpin is the
only significant or most significantly associated SNP in the region (miR-3615-3p, miR-3176-
3p, miR-4423-5p, miR-4707-3p). In these cases we can infer with reasonable confidence that
the selected SNP is likely to be the causal SNP affecting expression of the mature microRNA
as with whole-genome sequencing data we have near complete ascertainment of variation. Two
related unobserved types of variation could also be in LD with variants selected here; indels
often called with lower accuracy may be unobserved or under-observed in this data, and larger
segmental duplications/deletions may not have been detected e.g. miR-941 is known to be a
multi-copy tandem repeat[91].
Most often the selected intra-hairpin-SNP is amongst a group of SNPs which show similar
association as they are contained within a linkage disequilibrium block where a group of SNPs
are segregating together (miR-146a-3p, miR-1908-5p, miR-1304-3p, miR-4513-5p, miR-3130-
2-5p, miR-1255a-5p, miR-641-5p, miR-1307-3p, miR-92a-1-5p). In these cases it is difficult
to predict based on genetic evidence alone which SNP is likely to be the causal SNP, however
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the selected SNPs within the microRNA hairpin have the opportunity to affect expression
at more stages as they may also directly affect the processing of the primary and precursor
microRNA. This hypothesis is being tested experimentally by our collaborators in microRNA
processing assays. And in other cases the SNP selected is not the most significant cis-eQTL
for the microRNA (miR-618-5p, miR-4745-5p, miR-914-3-3p, miR-5680-3p, miR-4482-1-3p,
miR-4741-3p, miR-3188-3p). In these cases the selected SNP may be in weaker LD with a
causal SNP flanking the hairpin, or these SNPs may have independent effects on expression.
Examining the LD between these SNPs could help to determine the independence of their
effects and again processing assays could determine if the selected SNP had a causal effect.






1 rs73933241 miR-641 11.5 flank-3p n n
2 rs817478 miR-4423 5.6 flank-3p n n
3 rs174561 miR-1908 25.3 flank-5p n y[238, 239]
4 rs8054514 miR-3176 18.1 flank-5p n n
5 rs7247222 miR-3188 10.2 flank-5p n n
6 rs641071 miR-4482-1 9.4 flank-5p n n
7 rs7911488 miR-1307 32.6 loop n y[240, 241]
8 rs745666 miR-3615 8.2 loop n n
9 rs2910164 miR-146a 36.0 miRNA-3p y[197, 242] y[243, 195,
242, 196]
10 rs28664200 miR-1255a 26.9 miRNA-3p n n
11 rs2273626 miR-4707 26.8 miRNA-3p n n
12 rs2155248 miR-1304 24.1 miRNA-3p n n
13 rs7227168 miR-4741 9.1 miRNA-3p n y[244]
14 rs2682818 miR-618 7.4 miRNA-3p y[245] y[246, 247]
15 rs2168518 miR-4513 18.4 miRNA-5p y[248] y[248, 249]
16 rs2427556 miR-941-3 17.7 miRNA-5p n n
17 rs9589207 miR-92a-1 16.1 miRNA-5p n y[250, 193,
251]
18 rs2241347 miR-3130-2 12.9 miRNA-5p n n
19 rs487571 miR-5680 12.1 miRNA-5p n n
20 rs10422347 miR-4745 6.2 miRNA-5p n y[252]
Table 6.1: Common microRNA cis-eQTLs, with expression associated to a mature microRNA
from the hairpin that variants are within or adjacent to. The pvalue and segment of the
microRNA hairpin the variant is within are listed. Where SNPs have been associated with
microRNA expression or traits previously the references are shown.
6.3.4 microRNA cis-eQTLs are also trait associated
Several microRNA cis-eQTLs identified here have been previously identified as trait or disease
associated SNPs, mainly from case-control studies. As molecular phenotypes are a priori good
functional candidates for cellular and organism level traits because risk variants often act by
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affecting aspects of gene regulation e.g. splicing QTLs which contribute as much to some traits
as eQTLs[253], I have explored other genetic associations of these common mpQTVs.
Cancer associated
miR-146a is transcribed as a primary microRNA with mir-3142. rs2910164 (G>C) changing a
G:U pair to a C:U mismatch in the stem loop is associated with increased expression of the 3p
mature microRNA but decreased expression of the 5p microRNA (Fig 6.3a). This microRNA
hand has been associated with the innate immune response[243] and identified as associated
with colorectal cancer risk (OR:1.34 95% CI 1.15-1.67) and survival (Hazard Ratio 2.12)[195]
and breast cancer risk (OR:1.77, 95% CI 1.40-2.24)[196]. Selection during the evolution of
metastasis has also been observed in two studies in differing ways: Jazdzewski et al. [197]
observed selection for the heterozygous state at this variant, with mutations from either the GG
or CC homozygote in 14 of 300 tumour/normal samples (4.6%). Forloni et al[242] observed
selection for the G allele for during the evolution of melanoma where in 8 of 15 cases a C
allele in the primary melanoma were mutated to G alleles in the primary metastasis including
heterozygote to GG mutations.
In colony forming assays melanoma cells stably expressing a miR-146a transcript with the
G allele formed more colonies than those with the C allele. This effect is suggested to be
due to the increased expression of mir-146a-5p which targets the NUMB mRNA - a regulator
of Notch signalling. Notch signalling having a key role in melanocyte development, usually
decreased in mature melanocytes and reactivation of Notch signalling required for melanoma
formation[242]. This locus also appears to be under strong selection with the ancestral G allele
conserved across most placental mammals however the C allele is at a high frequency in human
populations. Also there appears to be fewer heterozygotes for this SNP than would be expected
under Hardy-Weinberg equilibrium although for the 452 samples genotyped here the odds ratio
of 0.786 does not reach statistical significance (p=0.096).
miR-618 is located within an intron of LIN7A (a cell polarity complex component). rs2682818
(C>A) located in the 3p microRNA is associated with a decrease in the expression of the 5p
mature microRNA (Fig 6.3b). miR-618 has been observed as up-regulated in a number of
cancers including hepatocellular carcinoma and male breast cancer[246, 247]. Genotyping of
this SNP in in non-Hodgkin lymphoma (455 cases, 527 controls) found an elevated risk for
individuals with one or more copies of the A variant (OR: 1.65, 95% CI: 1.05-2.60).
miR-4741 is located within the retinoblastoma binding protein 8 (RBBP8). rs7227168 (C>T)
located within the 3p mature microRNA and is associated with a decrease in expression of the
3p mature microRNA (Fig 6.3m). This SNP has been associated with an increased mortality
risk in non-small cell lung cancer (Hazard ratio 1.35, 95% CI 1.11-1.65)[244].
miR-1307 is located within a cassette exon of up-regulated during skeletal muscle growth 5
(USMG5). rs7911488 (A>G) located within the terminal loop is associated with a decrease
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in expression of both the 3p and 5p mature microRNA (Fig 6.3q 3p shown as it is most
significant). This SNP has been associated with occurrence of colorectal cancer (OR: 1.29,
95% CI 1.13-1.46)[241] and has a proposed mechanism through the C allele creating a binding
site for exonic splicing enhancers MBNL1 which may either block Dicer processing[241] or
affect exon skipping[240].
miR-92a is part of the miR-17∼92 microRNA cluster which has been observed to
have amplifications and overexpression in cancers[250] and deletions leading to growth
defects[193]. rs9589207 (G>A) located in the 5p mature microRNA is associated with an
increase in expression of the 5p mature microRNA (Fig 6.3t). The SNP has been associated
with decreased risk of gastric cancer with a possible mechanism in altering the binding to
FBXW7 - a protein involved in cell proliferation which has been related to tumour pathogenesis
- leading to upregulation in presence of the AA genotype[251].
Blood lipid traits
Examining trait associations based on expression in LCLs will miss many associations relevant
to other cells and tissues, however blood lipid traits may be the most relevant traits to this cell
type.
miR-1908 is located within an intron of FADS1 (fatty acid desaturase 1A). rs174561 (T>C)
located in the 5p basal stem is associated with an increase in expression of the mature 5p and
3p microRNA (Fig 6.3d 5p shown as this association was most significant). mir-1908 is known
to be highly expressed in mature human adipocytes with expression level affected by obesity
and insulin sensitivity factors[238]. rs174561 has been associated with LDL-cholesterol, HDL-
cholesterol, total cholesterol, triglyceride, and fasting glucose. However nearby SNPs in LD
with rs174561 were also associated with these traits making the identification of the causal
variant difficult[239].
miR-4513 is located within an intron of CSK (c-src tyrosine kinase). rs2168518 (G>A) located
within the seed region of miR-4513-5p is also associated with a decrease in expression of the
5p mature microRNA (Fig 6.3f). This SNP has been associated with fasting glucose, low-
density lipoprotein, cholesterol, total cholesterol, systolic and diastolic blood pressure, and
risk of coronary artery disease[248, 249].
Other traits
miR-4745 is contained within an intron of he PTBP1 (polypyrimidine tract binding protein)
adjacent to an exon and potentially processed as a mirtron where the pre-microRNA is excised
by the spliceosome. rs10422347 (C>T) located at position 18 of the 5p microRNA is
associated with a decrease in the expression of the 5p microRNA (Fig 6.3c). However other
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nearby microRNAs are more strongly associated with expression. rs10422347 is in LD with
SNPs in the PTBP1 gene associated with reduced insulin release[252].
6.3.5 SNPs with known microRNA processing effects are recovered
Within these identified cis-eQTLS were several cases of SNPs with experimentally validated
effects on microRNA processing rather than pri-microRNA production. Although, without
exception the mechanistic basis of that processing change has not yet been demonstrated.
miR-618
The effect of rs2682818 on the mature microRNA level of miR-618 described above as a
risk factor in several cancers and is shown in Fig 6.3b has been observed in HeLa cells
where transfection with both G and T allele microRNA precursor expression vectors had
approximately similar effects on the levels of precursor transcripts (10.6- and 9-fold increase)
whereas the G allele expression vector increased the mature microRNA transcript levels 5-fold
the T allele vector led to an increase of mature microRNA 2-fold, suggesting an effect in one
of the post-transcriptional processing steps[245].
miR-146a
The effect of rs2910164 on expression of miR-146a-5p described above as selected for in
colorectal cancers and shown in Fig 6.3a has been seen previously seen in an in vitro processing
assay where in HeLa nuclear extract pre-miR-146a was produced at a two fold higher level
from a G allele primary transcript compared with a C allele primary transcript, demonstrating
a differences between the two alleles in the efficiency of pre-microRNA production in the
nucleus[197]. This effect has been replicated by Forloni et al. who observed a higher level of
miR-146a using an expression vector with the G allele than with the C allele in three different
cell types[242].
miR-4513
The effect of the mutant A rs2168518 allele on lowering the production of miR-4513 described
above associated with various blood glucose traits and is shown in Fig 6.3f has also been
demonstrated through transfection of expression plasmids with wild type or mutant pre-miR-
4513 and GFP into HEK293 cells assaying the levels of these by qPCR[248].
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6.3.6 A reciprocal response from miR-146a to a cis-eQTL
rs2910164 in miR-146a discussed above as a cancer associated associated processing variant at
a locus under strong selection in the human population shown in Fig 6.3a has previously been
described as increasing the expression of the mature 5-prime microRNA[197, 242]. This effect
could also be seen in this study with the median G/G genotype expression 9% higher than the
median C/C genotype expression, however the result was not significant after multiple testing
correction. A 3p microRNA from this locus was also seen with three orders of magnitude lower
expression than the 5p microRNA (miR-146a-5p being the 4th most abundant microRNA).
rs2910164 was seen as a significant eQTL for miR-146a-3p after multiple testing correction,
with the C/C genotype having expression about double that of the G/G genotype.
This result suggests a reciprocal response to the SNP where the G allele is associated with an
increase of the 5p microRNA (as has been experimentally validated) and a decrease of the 3p
microRNA, suggesting a novel possibly competitive effect in the processing of this hairpin.
The effect of SNPs on microRNA expression where there is expression data for both 5p and
3p products is shown in Fig 6.4, for cis SNPs within 1kb of a microRNA. The correlation of
rs2910164 and another SNP in strong LD with miR-146a was unique in showing an opposite
response by the 5p and 3p microRNAs. All other cis-eQTL SNPs (FDR<1%) the correlation
with expression was always in the same direction for both the 5p and 3p microRNA.
6.3.7 Rare variants are cis-eQTLs
Common variants are unlikely to manifest as highly penetrant deleterious phenotypes as
selection will tend to reduce their frequency within the population. Consequently, rare SNP
eQTLs may be more likely to have large effects expression levels and subsequently more
deleterious effects on phenotypes, although the power to detect them is lower than for common
variants.
This analysis has identified 12 rare microRNA cis-eQTLs which were present in either the
microRNA terminal loop or flanking the mature microRNA (Table 6.2.
Boxplots showing the effect on expression for these 12 cis-eQTLs are shown in Fig 6.5, and
locus plots are shown in Fig 6.6 for 11 regions as two SNPs are selected as cis-eQTLs for
miR-769-5p. In some cases such as the SNPs selected for miR-106b and miR-576 the selected
SNP in the hairpin loop is the most significant within the region. However in other cases
other similarly significant or more significant cis-eQTL SNPs are present near the microRNA
locus. In these later cases performing multivariate linear regression using the genotype values
of multiple SNPs to explain the expression changes allows us to see if one SNP has a significant
effect in explaining expression when the effects of other SNPs have been taken into account.
For example in the case of miR-5701 a SNP 150bp downstream of the locus is most significant
with a -log10 pvalue of 3.7 whereas the SNP within the microRNA hairpin has a -log10 pvalue
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Figure 6.3: Left: Regional association plots (x-axis) genomic distance from microRNA, (y-
axis) -log10 pvalue. Centre: microRNA expression boxplots (x-axis) genotypes with number of
samples, (y-axis) normalised microRNA expression level. Right: schematic of the microRNA
locus with mature microRNA(s) shown in grey, variant shown in red.
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Left: Regional association plots (x-axis) genomic distance from microRNA, (y-axis) -log10
pvalue. Centre: microRNA expression boxplots (x-axis) genotypes with number of samples,
(y-axis) normalised microRNA expression level. Right: schematic of the microRNA locus with
mature microRNA(s) shown in grey, variant shown in red.
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Left: Regional association plots (x-axis) genomic distance from microRNA, (y-axis) -log10
pvalue. Centre: microRNA expression boxplots (x-axis) genotypes with number of samples,
(y-axis) normalised microRNA expression level. Right: schematic of the microRNA locus with
mature microRNA(s) shown in grey, variant shown in red.
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Left: Regional association plots (x-axis) genomic distance from microRNA, (y-axis) -log10
pvalue. Centre: microRNA expression boxplots (x-axis) genotypes with number of samples,
(y-axis) normalised microRNA expression level. Right: schematic of the microRNA locus with
mature microRNA(s) shown in grey, variant shown in red.
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Left: Regional association plots (x-axis) genomic distance from microRNA, (y-axis) -log10
pvalue. Centre: microRNA expression boxplots (x-axis) genotypes with number of samples,
(y-axis) normalised microRNA expression level. Right: schematic of the microRNA locus with
mature microRNA(s) shown in grey, variant shown in red.
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Left: Regional association plots (x-axis) genomic distance from microRNA, (y-axis) -log10
pvalue. Centre: microRNA expression boxplots (x-axis) genotypes with number of samples,
(y-axis) normalised microRNA expression level. Right: schematic of the microRNA locus with
mature microRNA(s) shown in grey, variant shown in red.






























































































































































































































































Left: Regional association plots (x-axis) genomic distance from microRNA, (y-axis) -log10
pvalue. Centre: microRNA expression boxplots (x-axis) genotypes with number of samples,
(y-axis) normalised microRNA expression level. Right: schematic of the microRNA locus with
mature microRNA(s) shown in grey, variant shown in red.





























































Figure 6.4: Correlation of variants with 3p and 5p mature microRNA expression from the same
locus within 1kb. (X-axis) correlation with the 3p mature microRNA. (Y-axis) correlation with
the 5p mature microRNA.
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microRNA chr pos maf -log10(pvalue) location
1 miR-4786-5p 2 240882519 0.003 1.676 flank-5p
2 miR-576-5p 4 110409962 0.008 2.896 flank-3p
3 miR-2277-5p 5 92956409 0.029 5.325 stem 3p
4 miR-1303-3p 5 154065348 0.030 2.886 stem-5p
5 miR-1303-5p 5 154065348 0.030 2.436 stem-5p
6 miR-589-5p 7 5535434 0.011 4.528 flank-3p
7 miR-106b-3p 7 99691652 0.008 2.890 loop
8 miR-96-5p 7 129414514 0.004 2.396 flank-3p
9 miR-5701-1-5p 15 21145671 0.068 2.200 flank-3p
10 miR-4513-5p 15 75081115 0.009 3.021 flank-5p
11 miR-769-5p 19 46522189 0.004 2.488 flank-5p
12 miR-769-5p 19 46522298 0.004 2.488 stem 3p
Table 6.2: Rare microRNA cis-eQTLs identified in the GEUVADIS dataset using linear
regression with the R package MatrixeQTL. Minor allele frequency(maf), pvalue and location
of the variant in the microRNA hairpin shown.
of 2.2. Multivariate regression demonstrates that the effect of the hairpin SNP disappears when
the most significant is taken into account, as these SNPs are in linkage disequilibrium (r2 =
0.6).
In the case of miR-96-5p the most significant SNP is located 750bp downstream of the
microRNA locus with a -log10 pvalue of 3.3 whereas the SNP in the hairpin has a -log10
pvalue of 2.4 (Fig 6.6). The regression analysis demonstrates that these SNPs are independent
and the significance of the hairpin SNP remains after the more significant SNP is taken into
account.
These selected rare SNPs increase the number of potential mpQTV and increase the power for
subsequent analysis of precursor regions and motifs to determine which are most often altered
in mpQTVs.
6.3.8 Primary hairpins are enriched for cis-eQTLs
SNPs within the whole stem-loop structure have an odds ratio of 5.6 for being a cis-eQTL
compared to SNPs flanking hairpins up to 1kb this confirms my prior expectation that loci
within the hairpin are more likely to affect microRNA levels than those without.
Examining each segment of the hairpin individually it can be seen in Fig 6.7 that several
segments within the stem seem to contribute to this signal, despite the small numbers of SNPs
in some segments in this analysis, leading to large error bars. SNPs in the 5p stem, hairpin
loop, and mature microRNAs having odds ratios of 14-28 (20-45% of SNPs in these regions
are cis-eQTLs) with error bars which do not overlap the null expectation demonstrating that
these regions are enriched in microRNA cis-eQTLs.





























































































































































































C/C (446) A/C (5) A/A (1) T/T (427) C/T (23) C/C (2) T/T (427) C/T (23) C/C (2)
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Figure 6.5: Rare variant cis-eQTL associations. (x-axis) Genotype and number of
individuals. (y-axis) microRNA expression (normalised read count). Variants are labelled
by chromosome position
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Figure 6.6: cis-eQTLs within the region for each selected microRNA. (x-axis) distance from
microRNA (bp). (y-axis) -log10 P value for each SNP. Red points: Selected rare cis-eQTL
SNPs within primary microRNAs. Black: Other SNPs































Figure 6.7: Odds ratio of containing microRNA cis-eQTLs for different regions of microRNA
hairpins. Calculated by Fisher’s exact test comparing to SNPs within 1kb of microRNA hairpin
loci excluding those within. Number of SNPs is shown in parentheses. Asterisks denote
significance p<0.05 with Bonferroni multiple testing correction for n=8 tests.
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6.4 Chapter summary
SNPs are present across microRNA loci, and derived allele frequency tests demonstrate
evidence for purifying selection above the genome-wide background at microRNA loci.
Previous studies have identified a number of variants associated with microRNA expression
levels but few have been investigated to identify causality and determine the mechanisms
involved. I have identified candidate microRNA processing variants from common and rare
polymorphisms which are cis-eQTLs for the microRNA loci they are within or adjacent to
using publicly available whole-genome and short RNA sequencing data in LCLs from the 1000
Genomes Project and the GEUVADIS consortium.
Despite the fact that the discovery of potential mpQTVs in this analysis is limited to
those microRNAs commonly expressed in LCLs a number of SNPs previously identified as
expression QTL or trait associated SNPs were seen. This includes rs2910164 in miR-146a
which has been observed to affect expression of the mature microRNA and is recapitulated as
a frequent somatic mutation in several cancer types, and rs2682818 in miR-618 which has also
been previously identified as a microRNA eQTL and risk factor in several cancers. rs2910164
in miR-146a was also seen to have a reciprocal relationship to the 3p and 5p microRNA
products suggesting a novel competitive mechanism.
These candidate processing variants will require experimental validation to determine whether
the selected SNP is indeed causal for the expression change. Where this is the case the
mechanisms of these effects may be investigated. The mechanism in the case of miR-146a
with 3p and 5p mature microRNAs responding in opposite directions to the presence of the
eQTL SNP may be particularly novel.
Stratifying microRNA cis-eQTLs by the segment of the microRNA hairpin they are contained
within suggests that SNPs within the 5p-stem, mature microRNAs and terminal loop of the
hairpin are more likely to affect the expression level of the mature microRNA, leading to
phenotypic consequences.
6.4.1 Future Directions
These candidate microRNA processing variant SNPs are being investigated in microRNA
processing assays by our collaborators to determine if they are the causal variant, and if so
which stage of processing they affect: the cleavage in the nucleus by DROSHA/DGCR8,
export, or cleavage in the cytoplasm by DICER. Following on from this protein binding assays
and RNA structure analysis such as SHAPE and hydroxyl radical cleavage footprinting as used
by Fernandez et al[199] (section 1.7.4) can determine where effects are due to the disruption
or creation of protein binding motifs or changes in RNA structure. This analysis will lead
to a greater understanding of microRNA processing mechanisms and the effect that human
polymorphisms have on this process.
CHAPTER 6. MPQTVS 84
Where short RNA-seq and genome sequencing data are available in other - perhaps disease
specific - cells or tissues similar analyses could be performed to identify additional mpQTVs,
particularly for microRNAs not expressed in LCLs and in disease or trait relevant cell types.
As microRNAs are involved in the regulation of many cellular and developmental pathways,
and variants at microRNA loci may alter microRNA expression, common polymorphisms
and rare mutations at microRNA loci have been seen to predispose to certain cancers and to
cause mendelian traits (section 1.7.3). These loci are often ignored, not prioritised in genome
sequencing studies or variant prioritisation software. Chapter 7 will examine microRNA
variants in the context of exome sequencing studies of disease cohorts.
Chapter 7
MicroRNA variants in disease
cohorts
7.1 Introduction
microRNA disruption and disregulation has been implicated in a variety of diseases through;
expression levels being associated with disease outcomes, common polymorphisms being
associated with disease outcomes in case-control studies, and rare variants in two causing
developmental phenotypes (section 1.7.3).
microRNA loci are non-protein-coding regions of the genome which are frequently ignored in
sequencing studies where variant annotation pipelines such as SIFT[254] and PolyPhen[255]
score variants by the severity of their effect on proteins i.e. missense, nonsense, frameshift
as well as annotating splice site and UTR mutations. Predictive information about the
consequences of microRNA variation is lacking and few examples of microRNAs disrupted in
disease have been observed. However microRNA processing defects have a clear molecular
model whereby a change in microRNA expression can impact the expression of other
identifiable genes. These effects on microRNA production can be tested experimentally in
processing assays, and effects on target gene expression can be tested through transfection
with microRNA mimics or inhibitors followed by assaying gene expression.
Here I annotate microRNA variants in disease specific exome sequencing cohorts at the IGMM
with clinical collaborators willing to perform follow up analyses and access to patient samples
including larger collections of phenotypically similar patients. I identify microRNAs enriched
for rare variants in particular diseases, rare variants in microRNA loci which are predicted
to target genes which when disrupted are disease causing, potential pathogenic variants, and
examine the profile of variants around microRNA hairpins.
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7.2 Methods
7.2.1 Data
An in-house database of exome sequencing variants from disease cohorts studied at the IGMM
was used. Samples are exome sequencing of normal tissue in colorectal cancer, microcephalic
osteodysplastic primordial dwarfism (MOPD), cranio-facial malformation types including
Cornelia de Lange syndrome collectively called ’eye’, micro syndrome and myopia cohorts.
These variants are stored in a MySQL database which may be queried to select genes, variants,
or regions of interest. Numbers of samples for each disease cohort are shown in table 7.1. I
query this database selecting variants +/- 20bp of microRNA loci from miRBase v21[11]. Also
as was performed by the GEUVADIS consortium[186] microRNA hairpins where only one
mature microRNA was annotated a partner microRNA was defined through base pairing after
RNA structure prediction. This allows all microRNA loci to be annotated similarly, making
comparisons between loci consistent.
For the MOPD cohort some sequencing of trios (parents plus affected offspring) was performed
allowing me to screen for de novo mutations which are present in the affected offspring but not
the parents.
Project Samples
Eye developmental disorders 241




Table 7.1: Exome samples examined for mutations at microRNA loci
Target capture for exome sequencing in these samples had been performed using several
different platforms (TruSeq, AgilentV4, AgilentV5, Agilent38M, Agilent50M, SeqCapv3)
each with differing genomic coverage. For this reason minor allele frequency calculations and
comparisons to control populations will require taking into account the number of samples
from each cohort with coverage for each specific microRNA. For each microRNA I have
calculated the expected coverage in each disease cohort to give microRNA specific enrichments
and statistics.
Within the disease cohorts examined here several different modes of inheritance are expected:
Within the rare Mendelian disorders of MOPD and cranio-facial developmental disorders
causal variants are expected to be fully penetrant, either dominant de novo mutations or
recessive rare variants forming homozygotes or compound heterozygotes. Colorectal cancer
is a complex trait with likely contributions from many common and rare variants with low
penetrance.
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7.2.2 Filtering
Variants from the database were selected for presence within 20nt of a microRNA hairpin
(miRBase v21[11]). Common variants (MAF>0.01) in the 1000 genomes project[204] or
Exome Aggregation Consortium[209] (ExAC) were excluded as for the disease cohorts used
common variant analysis has already been performed, and other than the cancer cohort the
expected mode of inheritance is with recessive rare variants, and dominant de novo mutants.
Variants were also excluded if coverage in a particular sample was below 10 reads or had
a genotype quality score lower than 90 from the GATK variant caller[256]. Some common
variants remained in the results despite this filtering, many may be population specific variants
where cohorts had been acquired in a particular geographic region. For this region variants
were also filtered for within-cohort minor allele frequency (MAF<0.01).
7.2.3 Variant annotation
SNPs were annotated with their microRNA locus finding overlaps for their genomic
coordinates with bedtools intersect. Based on miRBase v21[11] annotation of microRNA
processing cleavage sites and stem-loop base pairing structure, each microRNA hairpin was
split into consecutive segments: 3p and 5p flanking the drosha cleavage site, 3p and 5p mature
microRNA, 3p and 5p mature microRNA seed sequence, and terminal loop. SNPs were then
annotated with their microRNA region accounting for microRNA strand orientation.
microRNAs were also annotated with their predicted targets from TargetScan v7[96], used to
analyse microRNAs which are predicted to target disease associated genes.
7.2.4 Burden analysis
Burden analyses for enrichment of variants at individual microRNA loci and at groups of loci
between cohorts are performed with Fisher’s exact tests using the R function fisher.test
from the stats package.
7.3 Results
7.3.1 microRNA loci are captured in exome sequencing
The majority of disease specific sequencing data currently available is exome sequencing.
In exome sequencing a DNA capture kit with specific hybridisation targets is used to select
the DNA molecules which are subsequently sequenced. This is a trade off between cost and
genomic coverage compared with whole genome sequencing. Exome capture kits frequently
also capture DNA from regulatory regions and non protein-coding genes, however this
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coverage can be inconsistent as some regions are captured more efficiently than others. Edge-
capture effects are seen where regions flanking targeted regions can be captured with low or
variable coverage. Off target capture may also occur where probes hybridise to regions other
than those they were designed to capture. Exome sequencing can efficiently identify SNPs
and small indels in the targeted regions, however detecting larger segmental copy changes is
difficult due to the non-uniformity of coverage.
microRNA coverage amongst the six different capture kits used to generate data in the in-
house database is shown (Fig 7.1 and Fig 7.2). In Fig 7.1 a Venn diagram for the number of
microRNA loci from miRBase v21 covered by five of the six platforms is shown. Of the 1870


































Figure 7.1: Venn diagram showing microRNA loci captured by five exome sequencing capture
platforms
Amongst miRBase v21[11] annotated high confidence microRNAs - annotated due to having
a high read coverage in shortRNA sequencing studies - the coverage by the target capture
platforms is better, with 74% to 97% coverage of the 295 high confidence microRNAs. A Venn
diagram showing the overlap in coverage for five of the six target capture platforms is shown
in Fig 7.2.


































Figure 7.2: Venn diagram showing high confidence microRNA loci captured by five exome
sequencing capture platforms
Filter CRC Eye MOPD micro myopia
None 380 872 1814 424 85
Quality score / read depth 349 789 1629 371 70
ExAC & 1000g maf < 0.01 203 330 762 70 7
Cohort maf < 0.01 271 320 1025 58 6
All filters 178 191 546 28 4
Table 7.2: Variants at microRNA loci remaining after filters are applied within each cohort.
Rare and Unique variants in exome sequencing at microRNA loci
Table 7.2 shows the number of variants remaining after applying minor allele frequency
and unique variant filters within each cohort. Most samples contain rare variants excluding
those with MAF>1% within the dataset (>75% of samples for CRC, eye, MOPD and micro
syndrome). Approximately half of samples contain variants which are unique within the pooled
dataset.
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cause samples In trio
known 73 27
unknown 102 36
Table 7.3: MOPD sample status. Causal variants had been previously identified for some of
the samples. Some samples also had parental exome data.
7.3.2 Variants are distributed across microRNA loci
1660 polymorphisms at microRNA loci were present in the database after excluding known
common variants, each found in between 1 and 217 individuals (median: 1, mean: 3.9). The
distribution of these polymorphisms across a standardised microRNA locus is shown in Fig 7.3.
Variants can be seen spread at similar frequencies across the whole length of microRNAs -
flanking regions, microRNAs and terminal loops - as was also seen looking at common variants
in dbSNP v139[208] (section 6.1).










Figure 7.3: Bar chart showing the count of variants present at each position in a standardised
microRNA locus
Within the rare Mendelian disorder samples it is expected that cases will generally arise due to
spontaneous de novo mutations or rare variants segregating in the population with a recessive
effect coming together as a homozygous or compound heterozygotes genotype.
In these analyses I identify de novo mutations where possible in the MOPD cohort, analyse
homozygous and potential compound heterozygous rare variants. I also aggregate rare variants
by microRNA locus and by microRNA predicted targets using Fisher’s exact tests to identify
microRNAs or groups of microRNAs enriched for rare variants.
7.3.3 De novo mutations in MOPD trios
MOPD samples were split into parental samples and cases. Cases were further split into those
where the cause of the disease is unknown and those where a putative causal mutation had been
identified in a known MOPD disease gene.
De novo variants could be identified through filtering for unique variants in those MOPD
samples which were present in a trio, assuming equal target capture and sequencing depth in
cases and parents. However as only variants added to the database are present, coverage in loci
where variants are not recorded is unknown, although if a variant is present with low coverage
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microRNA region group cause chr pos ref alt geno
mir-1299 flank-3p MOPD known 9 69002230 G C 0/1
mir-1299 loop MOPD unknown 9 69002276 C T 0/1
mir-4477a loop MOPD unknown 9 68415343 A G 0/1
mir-615 flank-3p MOPD unknown 12 54427841 C CGGA 0/1
Table 7.4: MOPD putative de novo mutants identified for those samples with parental
information where variants were present in the case sample but neither of the parental samples.
in a region it may be assumed that the region is not captured efficiently in other samples.
Four putative de novo mutations were seen in different MOPD cases(Table 7.4), three in cases
of unknown cause and one in a case with an identified causal mutation.
chr9-69002276:C>T in the terminal loop of miR-1299 was seen in a case of unknown cause.
However at the same microRNA loci chr9:69002230:G>C in the 3p-flank was also seen as a de
novo mutation in an MOPD patient with a known causal mutation, suggesting that this variant
is unlikely to be causal. Nearby rs79965448 in the 3p mature microRNA is marked in ExAC
r0.3[209] as a low quality variant captured in only 257 individuals, suggesting poor coverage
in a parental sample may cause its de novo classification here.
chr9-68415343:G>A(rs71224722) in the terminal loop of miR-4477a was present in one case
of unknown cause, also seen in 47/1867 individuals in ExAC r0.3[209] where it is marked as a
low quality site making it possible that this region was not well captured in the parent samples.
This variant is also present in the J. Craig Venter genome[257] so not causal for a microcephaly
phenotype.
A 3bp insertion at chr12:54427841 in the 3p flank of miR-615 was seen in one MOPD case of
unknown cause. Other variants at miR-615 within ExAC r0.3[209] are reported as having low
coverage with mean coverage in the region of 5x.
These four putative de novo mutations in three microRNA loci are most likely false positives
due to these regions not being captured efficiently leading to the variants not being called in
the parent who carries it. Calling de novo mutants from bam files using specialised software to
take into account read depth in the three samples would likely be a way to reduce these false
positives.
7.3.4 Homozygote variants
Six samples with homozygous rare variants at microRNA loci are found excluding those on
the X chromosome, they are all from the MOPD cohort, four in cases of unknown cause, one a
parental control and one a case of known cause (Table 7.5). 17:79099125:G/C homozygote in
parental control sample 410 is heterozygote in their affected child who has an identified disease
causing mutation. Those in the four cases of unknown cause are singleton variants only seen
once in these cohorts. The 3:48357921:A/G variant in sample 583 is seen as a heterozygote in
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sample microRNA region group cause chr pos ref alt
411 mir-657 miRNA-5p MOPD control 17 79099125 G C
454 mir-92a-1 miRNA-5p MOPD unknown 13 92003581 T C
583* mir-2115 miRNA-5p MOPD unknown 3 48357921 A G
584* mir-520d flank-5p MOPD known 19 54223342 C G
587* mir-4524a flank-5p MOPD unknown 17 67095769 C T
608* mir-302d flank-3p MOPD unknown 4 113569157 C G
Table 7.5: Homozygous mutations at microRNA loci, candidates to affect both copies of the
microRNA. *These samples were added to the database later so have not been investigated
thoroughly
one ExAC r0.3 sample of 2780 with coverage. The 17:67095769:C/T variant in sample 587 is
seen as a heterozygote in one ExAC r0.3 sample of 2 with coverage. The other two variants in
samples 454 and 608 are not seen in ExAC r0.3 or the 1000 Genomes Project samples. Parental
genotypes are not available for these samples to identify the mode of inheritance. One of these
- sample 454 - with a homozygous mutant in the 5p microRNA of miR-92a is investigated
further below as this microRNA has been associated with disease relevant traits previously.
A homozygous variant in a trait associated locus
This homozygous variant of miR-92a-1 in an MOPD sample seemed particularly interesting
as the miR-17∼92 cluster of microRNAs has been previously implicated in the definition of
body size. De Pontual et al[193] reported germline hemizygous deletions of the miR-17∼92
microRNA cluster in three individuals with phenotypes consistent with Feingold syndrome
which includes microcephaly and short stature and without mutations in MYCN - a previously
established cause of Feingold syndrome. These individuals had approximately 50% expression
of all six microRNAs from the cluster measured by RT-qPCR in peripheral white blood cells.
An allelic series of mutant mice with engineered deletions of combinations of microRNAs
at the miR-17∼92 locus revealed specialisation and cooperation which can coexist between
members of the locus with larger deletions causing skeletal abnormalities and reduced
bodyweight. Deletion of miR-92 from this locus causing a∼20% reduction in bodyweight, but
this was the smallest size reduction phenotype of the targeted deletions from the locus[258].
Processing of microRNAs from this locus occurs in a complex series of steps where a
progenitor microRNA expressed from this locus containing the six microRNA hairpins is
dynamically regulated due to the presence of a repression domain at the base of the miR-
92a-1 hairpin controlling the folding of the RNA molecule inhibiting further processing by the
microprocessor[259].
The homozygous mutant at miR-92a-1 in the MOPD patient is a T>C change at the 4th position
of the 5p microRNA within the seed region. Expression of the 3p microRNA from this hairpin
is two orders of magnitude higher than the 5p microRNA in LCLs (Using expression data used
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in section 6), though both are highly expressed relative to other microRNAs with miR-92a-
1-3p being the 5th most highly expressed microRNA and miR-92a-1-5p being 160th, of 711
microRNAs expressed in >50% of samples LCLs.
Were this miR-92a-1 mutant to be causal for MOPD this could be due to the altered 5p
microRNA seed sequence, altered processing of the miR-92a-1 hairpin by the microprocessor,
or altered processing of the miR-17∼92 cluster.
The observation of a homozygous novel variant is surprising and suggests the variation may be
hemizygous, opposite a deletion (implying Feingold syndrome). Alternatively, it may indicate
consanguinity or more distant identity by decent. Examining the overall level of homozygosity
in this patient revealed that they are consanguineous, with 15-20% of the genome in large
(>1.5mb) runs of homozygosity depending on the tool used to calculate this. Discrepancies
between methods for measuring runs of homozygosity may be expected as coverage in exome
data is highly non-uniform. Using sliding windows across the genome of 1Mb requiring 100
SNPs in a window PLINK[260] finds 18% of the genome to be in runs of homozygosity.
H3M2[220], a tool designed to identify regions of homozygosity from whole-exome data using
a hidden Markov model, finds 16% of the genome in large runs of homozygosity. These percent
homozygous scores would be consistent with a first cousin marriage. The miR-17∼92 cluster
on chromosome 13 is identified as within a run of homozygosity by both of these tools (Fig 7.4).
As this patient has multiple large runs of homozygosity other variants may be causative for the
MOPD phenotype, although none have been identified in known disease causing genes. This
patient has 121 nonsense or missense variants which pass quality filtering, 12 homozygous
and 109 heterozygous. These variants can be examined for their predictive effect on the target
protein and how that protein is connected to known disease linked pathways. Examining just
the homozygous or compound heterozygous variants 13 genes contain variants with varying
levels of uniqueness, effect on the protein and likelihood of protein to be linked to MOPD.
A novel variant in FGFR2 - involved in embryonic development of blood vessels and bone -
would seem the most likely of these to be causative given its connection to embryogenesis,
although the variant is predicted as tolerated/benign by sift/polyphen. None of these other
homozygous mutants represents a unique variant predicted to be deleterious to protein function
with a protein connected to DNA replication / DNA repair.
7.3.5 Compound heterozygous variants
Another expected mode of inheritance for the rare Mendelian disease cohorts is multiple rare
variants at a locus affecting both copies of a gene. 37 samples from the database have multiple
rare variants at the same microRNA locus (table 7.6). Many of these will be clusters of variants
in LD which are segregating together in the population, present on only one copy of a locus.
Differentiating these cases from genuine compound heterozygosity would require examining
the parental genotypes or examining reads spanning these loci in the original bam files. An








Table 7.6: Sample counts for potential compound heterozygotes, microRNA loci with multiple
mutations in the same sample where potentially both copies of a microRNA are affected.
analysis not possible using only the variant database here.
7.3.6 microRNA loci with multiple cohort specific rare variants
Here I perform a burden analysis of rare variants at microRNA loci identifying loci with rare
variants in multiple individuals from the same disease cohort, a key method of identifying
disease causing genes[261]. I contrast these with rare variants in individuals from other cohorts
in the database having expected coverage for each microRNA. The expected coverage of
microRNAs for each individual is based on the capture platform used in their exome sequencing
(section 7.3.1). Fisher’s exact tests are performed for each microRNA locus to identify those
with significant enrichment in one disease cohort above a background rate using variants at all
other loci. One confounding factor in this analyses is that each disease cohort is recruited from
populations of differing geographic location, causing population stratification which may lead
to false positive enrichments where population specific variants exist. While the majority these
variants are heterozygote and expected mode of inheritance in the Mendelian disease cohorts
is often recessive rare variants, it is possible that additional mutants nearby may be missed due
to low or no coverage in the exome target capture kits, or nearby segmental copy changes may
be difficult to identify in exome sequencing.
MOPD
In the burden analysis comparing MOPD cases of unknown cause with controls and those of
known cause two loci passed nominal significance with rare variants in only three cases of
unknown origin at each loci (tables 7.7, 7.8). Both of these were not robust to Bonferroni
multiple testing correction.
miR-758 had rare variants in three MOPD cases with no known disease causing mutation, each
heterozygous mutants in the 5p flanking region with good read coverage. Two of these variants
are also seen in ExAC r0.3 and the variant in sample 585 is also seen in two samples from the
Eye cohort. Two other variants at this locus are also present in the database also seen in ExAC
r0.3 in the 5p mature microRNA in a colorectal cancer sample and in the terminal loop in a
sample from the eye cohort (table 7.8).
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microRNA cohort samples coverage others samples others coverage pvalue
mir-758 MOPD 3 110 0 222 0.038
mir-4289 MOPD 3 96 0 191 0.039
Table 7.7: microRNA loci enriched for rare variants in MOPD cases of unknown cause.
Numbers indicate the counts forming a contingency table used in a Fisher’s exact test for
samples with coverage in the named microRNA and all other microRNAs in this cohort
compared to others, pvalue shown
microRNA chr pos region maf group samples
mir-4289 9 91360766 miRNA-3p 0.00539 MOPD 2
mir-4289 9 91360814 flank-5p 0.00030 MOPD 1
mir-758 14 101492341 flank-5p 0.00003 MOPD 1
mir-758 14 101492342 flank-5p 0.00040 Eye 2
mir-758 14 101492342 flank-5p 0.00040 MOPD 1
mir-758 14 101492362 flank-5p MOPD 1
mir-758 14 101492383 miRNA-5p 0.00002 CRC 1
mir-758 14 101492407 loop 0.00023 Eye 1
Table 7.8: All variants at microRNA loci selected as enriched for MOPD variants
miR-4289 had rare variants in three MOPD cases of unknown cause: at one site in the 3p
mature microRNA seen in two cases and a site in the 5p flank seen in one case. These are not
seen in other samples in the database, but are both seen in ExAC r0.3.
Other cohorts
For the remaining cohorts where well matched control populations were not available each
cohort was contrasted with all other cohorts when testing for enrichment of rare mutations
at microRNA loci. After applying a Bonferroni correction for multiple testing only three
microRNA loci had significant enrichments, all in the micro syndrome cohort (table 7.9).
In miR-147a where two variants were each seen in the same four samples with micro syndrome,
not present in ExAC r0.3. Also present in this locus was a variant seen in two other cohorts in
the database as well as in ExAC r0.3 (table 7.10).
Variants in miR-365a and miR-6874 were also seen in three and four samples with micro
syndrome respectively, not seen in other cohorts in the database but both seen in ExAC r0.3.
These three significant enrichments after multiple testing correction in the Micro syndrome
cohort are due to five samples with the same rare variants present amongst three or four of
the samples at these loci. These signals may be due to a population specific effect from these
samples, which have the same combinations of rare variants, not seen in other cohorts which
are predicted to have coverage at these loci.
Within the colorectal cancer cohort there were four microRNA loci with nominal significance
for enrichment of rare variants (table 7.11), none significant after multiple testing correction.
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microRNA cohort samples coverage other samples others coverage pvalue
mir-147a Micro 4 35 2 1260 9.940E-06
mir-6874 Micro 4 35 0 573 1.421E-05
mir-365a Micro 3 35 0 1260 2.320E-05
Table 7.9: microRNA loci enriched for rare variants in the Micro syndrome cohort. Numbers
indicate the counts forming a contingency table used in a Fisher’s exact test for samples with
coverage in the named microRNA and all other microRNAs in this cohort compared to others,
pvalue shown
microRNA chr pos region maf group samples
mir-147a 9 123007254 flank-3p Micro 4
mir-147a 9 123007266 miRNA-3p Micro 4
mir-147a 9 123007313 miRNA-5p 0.001997 MOPD 1
mir-147a 9 123007313 miRNA-5p 0.001997 CRC 1
mir-365a 16 14403139 flank-5p 0.000017 Micro 3
mir-6874 7 5751517 miRNA-5p 0.000008 Micro 4
Table 7.10: All variants at microRNA loci enriched for mutations in the micro syndrome cohort
microRNA cohort samples coverage other samples others coverage pvalue
mir-96 CRC 19 672 3 623 0.001
mir-499a CRC 6 672 0 623 0.032
mir-499b CRC 6 672 0 623 0.032
mir-3614 CRC 7 672 0 424 0.048
Table 7.11: microRNA loci enriched for rare variants in the CRC cohort. Numbers indicate
the counts forming a contingency table used in a Fisher’s exact test for samples with coverage
in the named microRNA and all other microRNAs in this cohort compared to others, pvalue
shown
microRNA chr pos region maf group samples
mir-3614 17 54968700 miRNA-5p 0.0023 CRC 7
mir-499a 20 33578188 flank-5p 0.0004 CRC 8
mir-499a 20 33578255 miRNA-3p 0.0008 CRC 4
mir-96 7 129414568 loop 0.0081 Eye 2
mir-96 7 129414568 loop 0.0081 CRC 12
mir-96 7 129414574 loop 0.0058 MOPD 1
mir-96 7 129414574 loop 0.0058 CRC 7
Table 7.12: All variants at microRNA loci enriched for CRC variants
Two variants in miR-96 present in 7 and 12 samples from the CRC cohort were also seen in 1
and 2 samples from other cohorts and were present in ExAC r0.3.
Within the cranio-facial developmental disease cohort (Eye) 19 microRNA loci passed nominal
significance (table 7.13), with none robust to Bonferroni multiple testing correction.
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microRNA cohort samples coverage others samples others coverage pvalue
mir-770 Eye 4 241 0 1054 0.001
mir-323a Eye 3 241 0 1054 0.007
mir-5196 Eye 4 241 2 1054 0.013
mir-4285 Eye 3 98 0 311 0.014
mir-4746 Eye 6 241 1 367 0.019
mir-26b Eye 3 241 1 1054 0.023
mir-6721 Eye 3 241 1 1054 0.023
mir-181d Eye 3 241 1 1054 0.023
mir-509-3 Eye 4 241 2 878 0.023
mir-1236 Eye 4 241 0 367 0.025
mir-1228 Eye 4 241 0 367 0.025
mir-874 Eye 2 241 0 1054 0.035
mir-34c Eye 2 241 0 1054 0.035
mir-199b Eye 2 241 0 1054 0.035
mir-635 Eye 2 241 0 1054 0.035
mir-99b Eye 2 241 0 1054 0.035
mir-128-2 Eye 2 241 0 1054 0.035
mir-516a-1 Eye 2 241 0 878 0.047
mir-3909 Eye 3 98 1 311 0.047
Table 7.13: microRNA loci enriched for rare variants in the Eye cohort. Numbers indicate
the counts forming a contingency table used in a Fisher’s exact test for samples with coverage
in the named microRNA and all other microRNAs in this cohort compared to others, pvalue
shown
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7.3.7 Mutations in microRNAs which target known disease genes
microRNA targets within 3'UTRs predicted by TargetScan v7 were analysed to see if previously
identified known causal genes are targeted by microRNAs which may have their effects
altered in these cohorts through mutation, either directly changing the sequence of the mature
microRNA or indirectly altering the expression of the microRNA. For each cohort a Fisher’s
exact test was performed contrasting microRNAs predicted to target disease implicated genes
with all other microRNAs, between the selected cohort and all other samples in the database.
Genes were selected where mutations were known to cause disease using published reviews
and internal up to date lists.
Genes containing mutations identified as causal in MOPD have been identified in a variety
of pathways, I have selected 45 based on published results: DNA damage response:
ATR[262], BLM[263], DNA2[264], LIG4[265], MRE11A[266], PNKP[267], XRCC4[264];
Centrasomal proteins: ASPM[268], PCNT[269], CEP152[270], CENPF[271], CENPJ[272],
CDK5RAP2[273], CPAP[272], NCAPD2[274, 275], NCAPD3[274]; The prereplicative
complex: ORC1[276, 277], ORC4[278, 277], ORC6[277], CDC6[277], CDC45[279],
CDT1[277]; Splicing machinery: RBM10[267], RNU4[280], U4atac[280]; And others:
ANKLE2[281], BCOR[282], CREBBP[283], DYRK1A[284], ERCC6[285], ESCO2[286],
FOXG1[287], KIF11[288], MED12[289], NDUFB3[290], NSUN2[291], PIK3R1[292],
PLK4[293], SIL1[294], SMARCAL1[295], SRCAP[296], TUBGCP6[297], VPS13B[298].
For the eye developmental disease cohort 11 genes were selected as linked to eye development
based on published reviews[299, 300]: CHX10[301], RAX[302], PAX6[303], BCOR[282],
SOX2[304], OTX2[305], RAB3GAP[306], STRA6[307], BMP4[308], SMOC1[309], and
FOXE3[310].
Five genes linked with micro syndrome were examined for mutations in microRNAs predicted
to target them: RAB3GAP1[306], RAB3GAP2[306], RAB18[311], TBC1D20[312], and
ITPA[313].
Colorectal cancer implicated genes used were also used to examine mutations in microRNAs
predicted to target them: APC[314], TP53[315], KRAS[316], PIK3CA[317], FBXW7[318],
SMAD4[319], TCF7L2[320], NRAS[316], BRAF[321], SMAD2[322], PCBP1[323].
Results for the Fisher’s exact tests are shown in table 7.14, no cohort was significantly enriched
for rare variants in microRNAs targeting disease implicated genes. Due to the relatively small
sample sizes of the cohorts in this analysis the power to detect a signal here is low. Where
larger sample sizes are available this analysis may be more likely to detect a signal.
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group target group non target group target others non target others pvalue
MOPD 20 34 34 65 0.86
Eye 24 48 103 244 0.57
Micro 2 8 118 284 0.73
CRC 116 137 123 155 0.73
Table 7.14: Fisher’s exact tests for enrichment of samples with rare mutations in microRNAs
targeting disease implicated genes for each cohort
7.4 Chapter summary
microRNA loci are non-protein-coding regions of the genome which are frequently overlooked
in disease genetics and variant annotation pipelines as predicting the effect of variants on
microRNA function is an ongoing problem.
As the amount of whole genome sequencing of patients increases this will become a more
pressing issue, and as I have shown many microRNA loci are captured by existing exome
capture kits frequently used in current patient sequencing studies.
As with common variation (section 6.3.1) rare variants are distributed across microRNA loci.
Distinguishing pathogenic variants from non-pathogenic will require analyses such as those
demonstrated here identifying loci enriched for variants in large disease cohorts. Use of
microRNA targeting databases can also identify those microRNAs which are more likely to
be functionally relevant to disease.
I have performed these variant prioritisation analyses in both rare Mendelian disorders and in
the common late onset disease colorectal cancer:
In MOPD samples with no known causal mutation I have identified several homozygous
variants at microRNA loci, investigating one in a patient were this variant is in miR-92a, a
member of a microRNA cluster where deletion studies have shown skeletal and body size
malformations. While consanguinity in this sample and potentially others will cause segments
of the genome to be in runs of homozygosity, increasing the number of potential disease
causing variants, where standard screening methods in protein coding genes have so far failed to
identify a causal mutation microRNA loci are interesting candidates. Screening for additional
mutations at the miR-92a locus is currently being performed by our collaborators in larger
cohorts of patients with similar phenotypes which have not undergone this exome sequencing
as additional cases with mutations at his locus would be compelling evidence for causality and
further investigation of these variants.
Within the MOPD samples where trios had been sequenced I have identified four putative de
novo microRNA mutations at microRNA loci, however due to the exome capture method and
variant information available in the database used this analysis is enriched for regions which
are poorly captured, and it is likely that in the parents there is not sufficient read depth to call
these variants.
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I have performed burden analyses examining individual microRNA loci and groups of
microRNA loci where the mature microRNA is predicted to target a disease implicated gene,
contrasting each cohort with the other cohorts in the database. Grouping microRNA loci by
their predicted targets there was so significant enrichment for rare variants in cohorts which
target disease implicated genes. This may not be surprising due to both the low sample sizes
of the cohorts here, and the high false positive rate for microRNA target prediction algorithms.
Examining individual loci in a burden analysis for rare variants identified three significant
loci robust to Bonferroni correction in micro syndrome, and nominally significant variants
in the MOPD, cranio-facial malformation, and colorectal cancer cohorts. Where well matched
control populations are not available this analysis is likely to be enriched for population specific
rare variants due to founder effects. This may be the case for the nominally significant results in
the colorectal cancer and cranio-facial malformations cohorts, as well as the significant results
in the micro syndrome cohort. Where a well matched control was available in contrasting
MOPD patients with and without identified disease causing mutations two loci were only
nominally significant each with rare variants in three samples.
7.4.1 Future Directions
As cohort sizes become larger in exome and increasingly in whole-genome sequencing studies
additional attention will be focused on non protein-coding regions of the genome when standard
variant screening procedures do not identify causal mutations and when the heritability
of phenotypes cannot be explained. In investigating microRNA loci the complementary
approaches taken in this chapter can form the basis for identifying additional candidate disease
causing mutations.
Additional screening is being performed at the miR-92a locus where a homozygous variant in
an MOPD sample with no known disease causing mutation was identified as additional similar
cases with variants at this locus would provide compelling evidence to investigate the causality
of these variants.
The approaches taken here may also be applied to larger exome sequencing databases such as
the ExAC database[209], where although much phenotypic data is not available the power to
detect enrichments would be greater due to the larger sample sizes.






























































































































































Figure 7.4: Homozygosity across the genome in MOPD patient. (x-axis) chromosome position.
(y-axis) sliding window homozygosity for patient (black line) other samples from the same
capture platform interquartile range (grey ribbon). Predicted runs of homozygosity by H3M2
(pink). miR-17∼92 cluster (vertical black line in chromosome 13)
Chapter 8
Discussion
The main aims of this project were the use of computational resources to generate and test
hypotheses relating to microRNA production and functions: Firstly to examine the diversity of
microRNA targeting using CLASH data evaluating the evidence for competitive endogenous
RNAs (ceRNAs) and non-canonical microRNA functions. Secondly to examine the effect
of genetic variation on microRNA processing using publicly available data, and the effect of
genetic variation at microRNA loci in disease.
8.1 A pipeline for the analysis of CLASH data
Addressing the first of my project aims required the development of a pipeline for the analysis
of data from the cross-linking, ligation and sequencing of hybrids (CLASH) protocol[100].
When applied to Argonaute this protocol produces a subset of sequencing reads which are part
microRNA and part target sequence which the microRNA was paired with, as well as reads
which are simply the target sequence like that of a standard CLIP experiment.
In collaboration I have improved upon and published a pipeline for the analysis of CLASH
data, providing improvements to the run-time which out-performs an alternative method in
number and quality of hybrids identified. This pipeline is available online freely under GNU
license[202].
Building on this work I have also developed a pipeline for the analysis of CLASH data aligning
to a genomic database. Parameters for this pipeline were obtained from a parameter sweep to
maximise the number and quality of quality of hybrids, measuring quality through how well
microRNAs base-pair with their identified targets as no true positive dataset was known. This
pipeline has been applied for the identification of microRNA targets to address my first project
aim in chapters 4 and 5, and has also been used in genomic breakpoint mapping in cancer
within the IGMM[230].
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8.2 The genome-wide diversity in microRNA targeting
microRNAs are known to base-pair with a variety of transcript types, however they have been
mainly studied in the context of their canonical base-pairing with protein-coding genes 3'UTRs
leading to translational repression. The computational prediction of microRNA targets is a well
studied problem in computational biology with a variety of prediction algorithms published
with many false positive predictions expected due to the lack of overlap between algorithms
(section 1.4.2). Many current algorithms also limit the prediction of microRNA targets to
within the 3'UTRs of protein coding genes.
The CLASH dataset[101] used in chapters 4 and 5 represents the first high throughput
assay of direct microRNA–target identification, previously examined for protein coding genes
identifying different classes of microRNA targeting - primarily seed region, compensatory
3’ binding, non-canonical. Further examination of the clash dataset by the Bartel lab[96]
suggested that those non-canonical targets did not mediate repression of the target transcript,
despite microRNA binding.
These non-repressive interactions, as well as all interactions outside of protein-coding genes
3'UTRs will contribute to the pool of available microRNA targets and may also have additional
functions through the protein-protein interactions of Argonaute.
8.2.1 Competitive RNA activity
All targets of a microRNA will affect the microRNA:target ratio which in turn may affect
the level of repression due to the sequestration of microRNAs. Several cases of competitive
endogenous RNA transcripts have been described including pseudogenes, lincRNAs and
circularised exons formed by back-splicing.
Chapter 4 examined these transcripts for targets in the CLASH dataset, few targets were
identified with more microRNA targeting from a single microRNA than expected looking at
the overall distribution of microRNA targets.
While the previously identified miR-7 association with CDR1as was seen as the most
significant association between microRNA and circular RNA no other association with
predicted circular RNAs were robust to multiple testing correction.
Other transcripts with significant enrichment for multiple target sites of a specific microRNA
were TP73-AS1 with miR-125 and MAP3K1 with two members of the Let-7 family of
microRNAs, making them candidates for genuine microRNA targeting or competitive RNAs
acting to affect the level of free microRNAs available for repression.
Using RNA sequencing data to measure transcript abundance, a linear relationship could be
seen between transcript abundance and the level of CLASH binding to a transcript, which was
not present for intronic sequences. Modelling these interactions on a per-microRNA basis
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allowed the identification of transcripts with higher levels of binding than might be expected if
effects were purely stochastic, representing potential genuine canonical targets or competitive
RNA species.
Examining spatial clusters of all microRNA binding sites in chapter 5 identified regions of
transcripts which have multiple independent binding sites, biased towards highly expressed
transcripts. Examining Argonaute targets identified through the more dense dataset of all
CLASH reads provides clusters less biased towards highly expressed genes and may be
candidates sources of competitive RNAs.
8.2.2 non-canonical functions
Several papers have described the targeting of microRNAs or siRNAs to transcription start sites
or splice sites having an effect on those processes, usually through the interaction of Argonaute
with chromatin remodelling proteins or splicing factors.
microRNAs targeting transcription start sites were examined using the HEK293 cell type
specific FANTOM5 TSS derived from CAGE-seq[207]. This identified two microRNAs miR-
1307 and miR-935 each with target sites within 50bp of nine different TSS. While significantly
more than expected by chance in each case these microRNAs had a greater number of non-TSS
targets sites.
Similarly seven microRNAs were seen to target sites within 50bp of splicing donor or acceptor
sites more often than would be expected by chance, in each case representing between 50%
and 75% of targets, with miR-320 also having a specific peak of binding sites upstream of the
splicing acceptor site.
8.2.3 Future work
As the effect of microRNA repression, dependent on microRNA expression levels and target
site abundance, is cell-type specific. It is plausible that within specific cells or tissues transcripts
may be expressed which will compete effectively for microRNA targeting at a sufficient level
to affect their repression activity.
Within the dataset examined there are few transcripts with more target sites for specific
microRNAs than would be expected by chance. Studies in additional cell types identifying
cell-type specific transcripts and using target site prediction software, or direct CLIP/CLASH
assays may uncover these.
The activity of microRNAs and Argonaute affecting additional non-canonical processes
including transcription and splicing remains a controversial subject. In this dataset several
microRNAs were present targeting transcription start sites or splice sites more often than would
be expected by chance.
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Functional testing of these enrichments could be performed through transfection of cells with
microRNA mimics or microRNA inhibitors, assays of gene expression or splicing with site
specific qPCR or genome-wide via microarrays or RNA-seq.
8.3 The effect of genetic variation in microRNA processing
The processing of microRNA hairpins from within primary microRNA transcripts to produce
mature microRNAs is a multi-stage process occurring first in the nucleus where precursor-
microRNAs are excised from RNA hairpins by DROSHA/DGCR8. Pre-microRNAs are then
exported to the cytoplasm where further processing by DICER produces single stranded mature
microRNAs to be loaded into Argonaute proteins to form the RNA-induced silencing complex
(RISC).
Each stage of this production process may be dependant on the binding of proteins to sequence
motifs, or the presence of RNA structural features, each of which may be affected by sequence
variants.
Several studies have used DNA markers or genome-sequences with measures of small RNA
abundance to identify microRNA eQTLs, however they have not investigated the mechanisms
of these effects. Using data from the largest such study of small RNA sequencing in 465
samples sequenced as part of the 1000 Genomes Project[186, 204] I have identified rare and
common variants which are eQTLs for the microRNAs they are contained within.
As whole genome sequencing has been performed it can be investigated whether these variants
are the functional variants or whether other nearby variants may be responsible for this effect.
Several of these variants have also been associated with cancers and blood lipid traits.
Additionally one candidate processing variant for miR-146a displayed a reciprocal response
between 5p and 3p microRNA expression whereas all other microRNAs where a 3p and 5p
microRNA were expressed displayed the same direction of change, suggesting a different
mechanism in this case.
To aid in the prediction of candidate variants derived allele frequency tests were used to
examine the evidence for selection, and Fisher’s exact tests for eQTL activity of variants
within different microRNA hairpin components. Derived allele frequency tests demonstrated
that the microRNA loci considered while having more selective constraint than the genome-
wide background they had less selective constraint than protein-coding codons as a whole.
Examining individual components of microRNA hairpins the number of variants to be
examined became relatively small leading to large error bars, with the error bars of each
component overlapping, and 5p microRNAs showing evidence for positive selection with an
odds ratio less than 1, although not significantly. Similarly the odds ratio of variants of being
a microRNA eQTL was significantly higher for those within primary-microRNA stem loops
than in the flanking sequence. While examining microRNA hairpin components significant
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odds ratios were seen for the internal components of the stem with relatively large error bars
due to the small numbers of variants.
8.3.1 Future work
A grant application has been submitted to the European Research Council to follow up the
candidate microRNA processing defects with a battery of experimental approaches. Where
processing variants are confirmed they will be investigated further such as in the case of the
novel miR-30c-1 variant where SHAPE, hydroxyl radical cleavage footprinting, and protein
binding assays were used to examine the effect of a variant on RNA structure of the microRNA
hairpin and protein binding[199] (section 1.7.4).
Knowledge about which variants are likely to affect microRNA processing can then be applied
in computational tools for predicting variant consequences for the annotation of variants in trait
and disease sequencing studies.
Combining these molecular phenotypes (microRNA expression level), experimental testing
of microRNA processing and the measurement of downstream target expression by RNA-seq
could provide rapid mechanistic insight into the impact of common non-coding variation on
human traits.
Larger whole genome sequence datasets would provide additional variants for derived allele
frequency tests to aid in examining evidence for selection, also useful in the prioritisation of
variants.
8.4 The effect of genetic variation at microRNA loci in
disease
Several cases of genetic variants at microRNA loci have been seen to cause disease, however
variants at microRNA loci are often overlooked in variant annotation and pathogenicity
prediction tools.
In collaboration with clinically focussed research groups at the MRC HGU (including the
groups of A. Jackson, D.Fitzpatrick and M. Dunlop) I have used several in-house exome
sequencing studies totalling 1295 samples in a pilot study for the screening of variants at
microRNA loci to identify candidate pathogenic variants.
The use of these cohorts had the advantage that additional phenotypic information is available
and where any candidate variants are identified they can be followed up on in collaboration
with the disease genetic group.
Using disease models relevant for each disease, e.g. (1) rare recessive variants seen as
homozygotes or compound heterozygotes in the rare MOPD and cranio-facial developmental
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diseases. (2) Many common and rare variants of low penetrance contributing to disease
likelihood in colorectal cancer. I have screened variants for their potential pathogenicity. Due
to the small size of these datasets, the power to detect pathogenicity of variants through a
burden analysis where genes are mutated in several individuals is low. Particularly given the
lack of well matched controls, leading to population stratification between sample groups in
which population specific and disease causing variants are difficult to distinguish.
This study identified a proband that is homozygous for a private variant in miR-92a with
microcephalic osteodysplasic primordial dwarfism (MOPD). This sample from an MOPD
patient with no identified pathogenic variant in a disease relevant gene. This proband does not
harbour candidate causal variants in genes known to be associated with primordial dwarfism,
and hemizogysity for this locus leads to growth deficits in both humans and mice.
8.4.1 Future work
This study has shown that a majority of microRNA loci, and almost all high confidence
microRNA loci are captured in current exome sequencing capture kits. Screening of additional
exome sequencing datasets using the procedures used here would provide additional candidate
disease causing variants.
As the use of exome and whole-genome sequencing accelerates need for effective variant
screening pipelines will increase, particularly in the non-protein-coding regions of the genome
where effective tools are currently lacking.
Further elucidation of rules governing the effect of variants in microRNA processing and
targeting, through methods such as those applied this project, will be required to build those
tools.
Working in collaboration with the disease groups at the IGMM has meant that additional
sample information and follow up studies are easily available. Examining large cohorts such as
the ExAC dataset while potentially providing additional candidate variants would be difficult
to interpret due to the lack of phenotypic information about samples due to data sharing
restrictions.
The identified candidate processing variant in miR-92a is being followed up with screening of
sample panels from patients of similar phenotypes which have not been exome sequenced, and
testing in microRNA processing assays. Candidate processing defects such as this represent a
model for the future characterisation of transcribed non-coding nucleotide sequence variants.
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